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Abstract:  
 Equine metabolic syndrome, a condition characterized by obesity, insulin 
resistance (IR) or hyperinsulinemia, and laminitis is a common endocrine disorder of 
horses.  The mechanisms responsible for the development of equine obesity-associated IR 
and hyperinsulinemia remain to be elucidated.  Understanding of the pathophysiology of 
equine IR is critical for development of effective treatments.  The purpose of this study 
was to improve understanding of mechanisms of equine IR. 
 Based on existing literature in other species, we initially hypothesized that 
oxidative stress due to mitochondrial dysfunction within skeletal muscle of obese horses 
causes IR.  To address this, markers of oxidative stress, mitochondrial function and 
antioxidant capacity were evaluated in skeletal muscle of horses with and without IR.  No 
markers of impaired mitochondrial function or oxidative damage were associated with 
hyperinsulinemia.  Regulation of mitochondrial dynamics was altered with IR and 
hyperinsulinemia. 
 As oxidative stress did not appear to be the primary mechanism of equine IR, we 
hypothesized that skeletal muscle inflammation causes equine IR.  Markers of 
inflammation were measured within skeletal muscle and systemic circulation.  No 
positive associations between inflammation and IR or hyperinsulinemia were identified. 
Because investigations into two key mechanisms of skeletal muscle insulin 
resistance did not reveal a likely pathogenesis of IR, investigations were redirected to a 
more global approach of evaluating dynamic testing techniques to assess sites of insulin 
dysregulation.  We hypothesized that two commonly employed field tests, the oral sugar 
test (OST) and insulin response to dexamethasone test (IRDT) were comparable to the 
gold standard test of tissue insulin sensitivity, the hyperinsulinemic euglycemic clamp 
(HEC).  The HEC was not correlated with fasting insulin concentration or results of the 
OST or IRDT, suggesting that tissue insulin sensitivity is not the primary determinant of 
field test results, and may not be the primary defect in insulin dysregulation of obese 
horses. 
 In summary, the mechanism of equine IR and hyperinsulinemia remains to be 
discovered.  Additional investigations of dynamic testing in a population of 
hyperinsulinemic and normoinsulinemic horses may improve understanding of etiologies 
of insulin dysregulation in the horse and allow for further investigation into the 
pathophysiology of equine obesity-associated IR and hyperinsulinemia. 
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 LITERATURE REVIEW 
 
Obesity is an increasingly common condition of people and companion animals, 
including horses.1-4  In people, obesity is associated increased risk for cardiovascular disease,5 
type II diabetes,6 polycystic ovary syndrome,7 and osteoarthritis.8  In horses, obesity is associated 
with infertility, poor thermoregulation, exercise intolerance, insulin resistance, and laminitis.9  
Equine metabolic syndrome (EMS) is a term coined in 200210 to describe an emerging clinical 
syndrome in middle-aged horses consisting of obesity (generalized or regional), insulin resistance 
or hyperinsulinemia, and laminitis.  Clinical recognition of obesity and EMS continues to grow; 
however, the pathophysiological mechanisms leading to the development of obesity-associated IR 
in horses have not been elucidated.  Appropriate interpretation of diagnostic test results and 
identification of disease pathophysiology are critical for the development of effective 
preventative measures and treatments.
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Insulin mediated regulation of glucose homeostasis and insulin resistance 
Glucose is an important energy source for mammalian cells, and glucose homeostasis is vital 
to survival.  Blood glucose is derived from three sources: enteral absorption, gluconeogenesis and 
glycogenolysis.  Normally, post-prandial blood glucose concentration is primarily regulated by 
pancreatic insulin secretion and insulin-mediated glucose uptake by insulin-sensitive tissues, with a 
lesser influence by insulin insensitive tissues.11  Insulin is a peptide hormone secreted by the 
pancreatic β cells within the islets of Langerhans in response to hyperglycemia.  Insulin is 
synthesized in the endoplasmic reticulum as pre-pro insulin, consisting of an A chain, a B chain, and 
a connecting peptide (C-peptide).12  Pre-pro insulin is cleaved to pro-insulin, which is transported to 
the Golgi apparatus where pro-insulin hexamers are formed. C-peptide is removed by enzymes during 
secretion of the pro-insulin vesicle from the Golgi,13 resulting in the formation of insulin.	   Insulin and 
C-peptide are co-secreted into circulation.  Insulin binds to its receptor in insulin-sensitive tissues, 
allowing for activation of the insulin signaling cascade and glucose uptake by target tissues. Insulin-
mediated glucose disposal primarily occurs in skeletal muscle, adipose, and liver, with skeletal 
muscle being the largest insulin sensitive tissue depot.  Insulin resistance (IR) is defined as a 
decreased ability of insulin sensitive tissues to respond to insulin.14  In people, whole-body IR is 
generally a reflection of skeletal muscle IR, as skeletal muscle is responsible for approximately 85% 
of glucose disposal in a euglycemic, hyperinsulinemic state.15 
 In obese people, IR is generally considered to be an early finding of alterations in glucose 
homeostasis.16  Increased pancreatic beta cell secretion of insulin compensates for impaired tissue 
sensitivity, resulting in high circulating concentrations of insulin (hyperinsulinemia).  Over time, the 
pancreas loses its ability to compensate and will secrete insufficient amounts of insulin in response to 
hyperglycemia, resulting in a hyperglycemic, hypoinsulinemic state (type II diabetes mellitus).  The 
progression to type II diabetes in people is common.  In contrast, horses are rarely reported to develop 
type II diabetes.17 
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Role of obesity in IR 
In people, generalized obesity associated with the development of IR.18  Similarly, equine 
obesity is negatively correlated with IS19 and associated with an increased risk of hyperinsulinemia.20  
Identification of obesity may therefore help in identification of risk for IR.  In horses, a subjective 
scoring system exists for measurement of body fat.21  However, due to the inherent inter-observer 
variation in scoring, an accurate, objective method of assessing body fat is desirable.  The body mass 
index (BMI) is a measurement system devised in order to improve objective evaluation of generalized 
adiposity.22  Equine BMI is calculated using the following formula:22 
BMI = Body weight (kg)/ height at withers (m)2 
 In a study comprised mostly of Standardbred horses, BMI was found to correlate well with 
body condition score (BCS);22 however, a subsequent study found that BMI had a weaker association 
with BCS in a population of Thoroughbreds and ponies.23 These findings suggest that breed 
influences the relationship between BMI and BCS.  In addition to BMI, other morphometric 
measurements have been employed to identify generalized or regional obesity, including girth, 
abdominal girth, and length.23,24  In a research setting, deuterium oxide has been used to evaluate total 
body fat.  Deuterium oxide was found to correlate well with body condition score in lean or 
overweight animals (BCS ≤7), although predictive value was lost at higher body condition scores.25 
In addition to generalized obesity, regional adiposity appears be a characteristic of IR in 
people.  Location of fat accumulation also appears to be important.  Several lines of evidence suggest 
the presence of visceral adipose is a stronger predictor of IR than subcutaneous adipose in people, 
although this remains under debate.26  Similarly, horses with EMS often develop regional fat stores.  
Recognized adipose depot locations include the neck, withers, rump, and epaxial musculature. 
Ultrasound has been used to quantify adipose deposits along the ribs, rump, and ventral midline.27  
Excessive deposition of fat along the nuchal ligament is recognized as a “cresty neck.”  This fat depot 
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has been subjectively assessed via a cresty neck score (CNS)23 or objectively assessed via 
measurement of neck circumference.28  Both cresty neck score23 and neck circumference28 are 
correlated with insulin sensitivity.  
Complications of IR: Focus on laminitis 
Equine insulin resistance or impaired glucose tolerance are associated with several endocrine 
conditions in horses, including osteochondritis dissecans,29 equine metabolic syndrome (EMS) and 
pituitary pars intermedia dysfunction (PPID).30  Both PPID and EMS are associated with laminitis, a 
painful, performance limiting and life-threatening disease of the equine foot.  In both PPID and EMS, 
insulin concentrations correlate with laminitis severity.31  Karikoski et al. reported endocrine 
disorders as the most common underlying disease in horses presenting to a veterinary hospital for 
laminitis.32  In that study, 90% of laminitis cases were attributed to endocrine disease and 2/3 of the 
horses were hyperinsulinemic.32  Hyperinsulinemia has independently been demonstrated to induce 
laminitis in both horses33 and ponies,34 and IR is associated with the development of laminitis.35   
Laminitis may be broadly divided into two general categories: endocrinopathic and 
inflammatory. Both types of laminitis appear to be associated with separation of the basement 
membrane at the dermal-epidermal junction.36  However, mechanisms that cause lamellar breakdown 
vary between inflammatory models and endocrine models.  There are many natural causes of 
inflammatory-mediated laminitis, including strangulating intestinal lesions, inflammatory 
gastrointestinal disease (e.g., enteritis or colitis), metritis, and pleuropneumonia.37 Inflammatory 
models developed to mimic these conditions include carbohydrate overload and black walnut extract-
induced laminitis.  Inflammatory laminitis is characterized by perivascular leukocyte infiltration, 
upregulation of pro-inflammatory cytokine expression, and apoptosis with a subsequent increase in 
basement membrane degradation by matrix metalloproteinases (as reviewed in Katz and Bailey).36  
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The exact mechanism underlying endocrinopathic laminitis has yet to be determined,36 but 
does not appear to involve an initiating inflammatory stimulus.  Proposed mechanisms include 
alterations in glucose metabolism,38,39 vascular tone,40-42 or activation of insulin-like growth factor 
signaling pathways.43,44  
Equine metabolic syndrome: General overview 
 Equine metabolic syndrome (EMS) was a term created in 2002 to describe obesity-associated 
laminitis in horses,10 and was further characterized in 2010 in a consensus statement from the 
American College of Veterinary Internal Medicine.45  The term was chosen due to similarities 
between EMS and human metabolic syndrome.  Human metabolic syndrome is a cluster of risk 
factors for cardiovascular disease, including central obesity and two of the following four 
characteristics: fasting hyperglycemia, decreased high density lipoprotein cholesterol, hypertension, 
and hypertriglyceridema.46 
Equine metabolic syndrome is defined by the presence of obesity, regional adiposity, insulin 
resistance or hyperinsulinemia, and laminitis.45  Additional characteristics which have been reported 
include dyslipidemia,28,35,47 hyperleptinemia,28,47 seasonal (summer) hypertension,48 and changes in 
estrous cyclicity in mares.10  Owners frequently report these horses to be “easy keepers” (i.e., horses 
are able to maintain stable weight despite restricted intake).10  Horses with EMS tend to be middle 
aged (5-18 years old) horses.10,45  A breed predilection appears to exist with ponies, Morgans, Paso 
Finos, Peruvian Pasos, Arabians, Warmbloods, Saddlebreds, and Spanish Mustangs more likely to be 
affected.10,45,49   
Management of EMS consists primarily of lifestyle changes, including dietary restriction and 
exercise.  Dietary management should consist of restricted pasture access and elimination of grain 
from the diet.  Hay intake should be limited to 1-1.5% of body weight.45,49  Analysis of hay should be 
undertaken to ensure a low (<10%) non-structural carbohydrate (NSC) content.49 Vitamin and mineral 
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supplementation may be needed in cases of poor quality forage.45  Exercise may also be helpful for 
weight loss in horses that are not laminitic.  Moderate exercise performed four days per week 
facilitates loss of fat mass but does not ameliorate insulin resistance in overweight to obese horses.50  
Some equids appear resistant to dietary intervention;51 in these cases, pharmacologic treatment is 
warranted.  Available therapies that have been evaluated in the horse include levothyroxine, 
metformin, and pioglitazone.  Levothyroxine is a thyroxine analogue that has been demonstrated to 
help promote weight loss and insulin sensitivity in horses,52 and appears to exert no clinically 
significant adverse effects during short term (≤48 weeks) administration.53  At this time, 
levothyroxine is recommended for short term use only as the possibility of adverse effects with 
chronic administration has not been evaluated.  Metformin is an adenosine monophosphate-dependent 
protein kinase (AMPK) agonist54 that has been used in people to improve glycemic status.55  In 
horses, metformin was initially demonstrated to improve insulin sensitivity.56  Subsequent studies 
demonstrated limited oral bioavailability of metformin in ponies and horses.57,58 Pioglitazone, a 
peroxisome-proliferator activated receptor γ (PPARγ) agonist, has been demonstrated to promote 
insulin sensitivity in obese people.55  PPARγ is a regulator of adipogenesis and lipid and glucose 
metabolism.59  Administration to non-obese horses for twelve days did not improve insulin sensitivity 
indices,60 but this may be due in part to poor bioavailability in horses.61 Glyburide and glibenclamide 
are sulfonylureas that have been used as part of a combination therapy to treat equine type II 
diabetes.17,62  Sulfonylureas enhance secretion of insulin from functional pancreatic beta cells.63 
Additional research is needed to identify effective treatments for equine IR and obesity.   
Diagnosis of IR: General overview 
 Insulin resistance may occur due to increased insulin degradation or neutralization, decreased 
binding of insulin to its receptor, or impaired downstream signaling.64  Insulin resistance may be 
diagnosed by the presence of fasting hyperinsulinemia or various insulin and glucose proxies.65  
Although fasting measurements of glucose and insulin may allow for diagnosis of insulin 
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dysregulation, dynamic tests allow for evaluation of responses to a glucose and/or insulin challenge, 
which may allow for detection of abnormalities not identifiable with fasting measurements.14  
Multiple dynamic tests have been developed for evaluation of insulin sensitivity or oral glucose 
tolerance in people, and subsequently adapted for use in the horse.  Interpretation of test results 
requires a working knowledge of the relative contributions of tissue insulin sensitivity, enteral 
glucose absorption, and insulin secretion.  During an oral glucose challenge, incretin hormones may 
substantially alter insulin secretion.  Finally, glucose tolerance may be influenced by non-insulin 
dependent glucose disposal. 
In people, assessment of response of pancreatic beta cells to glucose or sensitivity of tissues 
to insulin is best achieved by use of clamps.66,67  There are two types of glucose clamps, the 
hyperglycemic clamp and the hyperinsulinemic euglycemic clamp.67,68  In the hyperglycemic clamp, 
an IV infusion of glucose is administered to allow for establishment of a fixed hyperglycemia.  In 
people, this hyperglycemic state suppresses hepatic gluconeogenesis and allows for assessment of 
sensitivity of pancreatic beta cells to glucose.67  The hyperinsulinemic euglycemic clamp (HEC) 
involves IV infusion of a supraphysiologic dose of insulin (3-6 mU/kg/min) and concurrent 
administration of glucose in order to maintain blood glucose within physiologic range.68-70 The 
maintenance of hyperinsulinemic euglycemia suppresses pancreatic insulin secretion, and thus allows 
for accurate assessment of tissue insulin sensitivity.  The HEC remains the gold standard for 
diagnosis of tissue insulin sensitivity.14,67  In horses, the hyperinsulinemic euglycemic clamp has been 
used to investigate insulin sensitivity in polysaccharide storage myopathy and the effect of exercise 
training on insulin sensitivity.69,70  Differences in insulin sensitivity have been identified between 
ponies and Warmbloods68 and Quarter Horses and Belgian horses.69,70  
The frequently sampled IV glucose tolerance test (FSIGTT) was initially developed as a 
technically more simple method to assess insulin sensitivity compared with the clamp,71 and was 
considered to be an improvement over the simple IV glucose tolerance test that had previously been 
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adapted for use in the horse.72 The IVGTT involves measurement of fasting blood glucose 
concentration, followed by measurement of glucose and insulin at 15, 30, 60, and 90 minutes and 
every hour for 5-6 hours thereafter.73 The FSIGTT requires more intensive sampling, but allows for 
improved separation of glucose and insulin kinetics, compared with the simple IVGTT.74,75  The 
FSIGTT involves administration of 300 mg/kg of glucose and blood sampling at time 0 (baseline), 1, 
2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 minutes.  
Glucose concentration is evaluated at all time points, while insulin concentration is evaluated at 0, 2, 
4, 6, 8, 10, 14, 18, 20, 30, 40, 60, 90, 120, 150, and 180 minutes.71  The insulin modified FSIGTT was 
developed in order to provide a more accurate assessment of tissue insulin sensitivity through 
administration of exogenous insulin.76  This involves IV administration of 300 mg/kg of glucose in 
the form of dextrose, followed (20 minutes later) by administration of insulin (30 mIU/kg).  In this 
test, blood samples are collected at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 22, 23, 24, 25, 26, 27, 30, 
35, 40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 minutes for measurement of plasma glucose and 
insulin concentrations.  In the insulin-modified FSIGTT, pancreatic response to glucose can be 
evaluated independently from tissue insulin sensitivity through minimal model analysis.  An insulin 
sensitivity index <1.0 is generally considered to be consistent with insulin resistance.77 
The combined glucose insulin tolerance test was developed as a simpler method of insulin 
sensitivity that may be employed in the field.78  This test consists of administration of a 150 mg/kg 
dose of glucose (50% dextrose) followed immediately by a 0.1 U/kg dose of insulin.  Blood is 
sampled for glucose at time 0 (baseline), 1, 5, 15, 25, 35, 45, 60, 75, 90, 105, 120, 135, and 150 
minutes, and diminished insulin sensitivity is considered to exist when glucose remains elevated 
above baseline for >45 minutes or insulin is elevated above 20 µIU at 75 minutes.78 Exogenous 
insulin allows for increased rate of glucose clearance compared to glucose alone.78 
The insulin tolerance test (also referred to as the insulin response test) involves administration 
of a 0.1-0.4 mU/kg dose of insulin and subsequent evaluation of glucose and insulin concentrations at 
9	  
	  
30-60 minute intervals for up to 6 hours.78,79  This test also directly assesses tissue insulin sensitivity, 
but may result in hypoglycemia.80  Recent data indicates that clinical signs of hypoglycemia may be 
avoided by using an abbreviated (30 minute) sampling period, with dextrose administered following 
the 30 minute sample point.80 
The dexamethasone suppression test (DST) was historically used as a dynamic test for 
pituitary pars intermedia dysfunction (PPID).81  However, a recent study found that ponies that were 
predisposed to laminitis had increased insulin concentration following dexamethasone administration 
(0.04 mg/kg IM), compared to control ponies.82  These ponies had normal cortisol concentrations, 
indicating that PPID was unlikely.  The reason for a more profound relative increase in insulin 
concentration relative to control ponies is not known.  In people, IV administration of dexamethasone 
enhances beta cell secretion of insulin in response to glucose,83 likely subsequent to impaired skeletal 
muscle insulin signaling within skeletal muscle.84 
 The oral glucose tolerance test (OGTT) was initially used in horses in 1973 to evaluate small 
intestinal malabsorption but was later used to evaluate glucose tolerance in equids.79  This test 
requires an overnight fast followed by administration of 1 g/kg of glucose via nasogastric tube.  Blood 
is drawn for measurement of blood glucose at time 0, 30, 60, 90, 120, 180, 240, 300, and 360 
minutes.  A peak in blood glucose is observed at 90-120 minutes after administration of glucose and 
should return to normal within 4-6 hours.85  More profound or prolonged hyperglycemia may indicate 
impaired pancreatic insulin secretion, decreased tissue insulin sensitivity or enhanced enteral 
absorption.  Results may be affected by stress of nasogastric intubation, diet, fasting, or age of 
equids.86-88 
The oral sugar test was the most recent field test of glucose tolerance to be investigated.49  
The test is performed by administering a 0.15 ml/kg oral dose of Karo syrup.   Blood is drawn for 
assessment of insulin and glucose at time 0 (baseline), and again at 60, 75 or 90 minutes.  An insulin 
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>60 µIU/ml at any time point is considered indicative of insulin resistance.49    Glucose and insulin 
response to an oral glucose challenge is influenced by enteral absorption, pancreatic insulin secretion, 
and tissue insulin sensitivity.89,90 During an oral glucose challenge, pancreatic insulin secretion is 
modulated by the incretin effect.91 Incretin hormones include the glucagon-like peptide 1 and the 
glucose-dependent insulinotropic hormones.  These hormones are released following an oral glucose 
challenge or following a meal, and have been shown to potentiate glucose-dependent insulin release.91  
The incretin effect is impaired in people with glucose intolerance and obesity.92  In people, the oral 
glucose tolerance test has been shown to have a strong correlation with the HEC, indicating that 
insulin sensitivity is the primary determinant of insulin response to an oral glucose challenge.93  The 
OST has been demonstrated to correlate well with the IVGTT in a population of normoinsulinemic 
and hyperinsulinemic horses,94 suggesting that either insulin secretion or tissue insulin sensitivity are 
the primary factors in response to an oral glucose challenge in horses. 
Mechanisms of obesity-associated IR: General overview 
Insulin resistance may occur secondary to decreased circulating concentrations of functional 
insulin, altered insulin receptor binding or impaired downstream intracellular signaling. The insulin 
receptor is a tyrosine kinase receptor with an α and β subunit. Insulin signaling is initiated by the 
binding of insulin to the α subunit of the receptor on the cell surface.12  The insulin signaling pathway 
is depicted in Figure 1.  Following binding of insulin, the β subunit of the insulin receptor 
autophosphorylates at tyrosine residues.  This phosphorylation allows for downstream activation of 
the insulin receptor substrate 1 (IRS-1) or IRS-2.  Following phosphorylation of the IRS protein, the 
phosphoinositol-3-kinase (PI3 kinase) is recruited to the plasma membrane.  The PI3 kinase catalyzes 
the conversion of phosphoinositol diphosphate (PIP2) to phosphoinositol triphosphate (PIP3).95  PIP3 
then activates protein kinase D (PKD) which activates protein kinase B/Akt.  Akt binds to its 
substrate, Akt substrate of kilodalton 160 (AS160), and phosphorylates several serine and threonine 
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sites, which inhibits AS160 from activating the GTPase activity of Rab.96  Rab becomes GTP loaded, 
allowing for movement of the glucose transporter 4 (GLUT4) vesicle from its cytosolic tether and 
insertion into the plasma membrane.96  Movement of the GLUT 4 vesicle also requires remodeling of 
the actin cytoskeleton and fusion of the glucose vesicle with the plasma membrane.97  In a basal state 
(i.e., unstimulated by insulin), <10% of GLUT4 is located at the cell surface, the rest existing 
intracellularly.98,99  Stimulation by insulin results in an increase in plasma membrane insertion,99  
although the number of vesicles translocated to the membrane is dependent upon regulation of the 





Figure 1.  Schematic of the normal insulin signaling pathway.   Insulin binds to the insulin receptor, 
phosphorylating the insulin receptor substrate-1 (IRS1) protein and activating the phosphoinsositol-3-
kinase (PI3 kinase). Protein kinase D (PKD) is recruited to the membrane and Akt is activated. 
Activation of Akt allows for inhibition of Akt substrate of kilodalton 160 (AS160), inhibiting its 
ability to activate the GTPase activity of Rab.   This allows for GTP loading of a Rab and 
translocation of the GLUT4 vesicle to the plasma membrane (see text for further details).  Dashed 
lines indicate inhibition, filled lines indicate activation.
	  
	   	  
































Interference with any part of this signaling pathway would theoretically cause insulin 
resistance.  However, the IRS1 appears to be a key regulatory site.101  Serine or threonine (inhibitory) 
phosphorylation of a number of residues can prevent tyrosine phosphorylation of the IRS1 and 
subsequent activation of the PI3 kinase.  The IRS1 is a site of inhibitory phosphorylation by stress 
kinases, including c-Jun kinase (JNK), protein kinase C (PKCθ), mitogen activated protein kinase 4 
kinase (MAP4K4), and inhibitor of nuclear factor kappa B kinase β (IKKβ).102,103  Stress kinases may 
be activated by a variety of intra- and extracellular signals, including di-acylglycerol (DAG), ROS, 
and inflammation.102-104 
In horses, insulin resistance has been associated with decreased GLUT-4 insertion within the 
membrane of skeletal muscle.105  Interestingly, the amount of GLUT-4 inserted in the membrane did 
not change in either IR or IS horses following in vitro stimulation of muscle with insulin.105  
Evaluation of phosphorylation patterns of AS160 indicate that the defect in insulin signaling is likely 
downstream of AS160.105  The mechanism responsible for the alteration in membrane-bound GLUT-4 
remains to be elucidated.   
Mechanisms of obesity-associated IR: oxidative stress 
Obesity-associated insulin resistance has been linked with increased cellular oxidative stress, 
both in insulin-sensitive tissues and systemic circulation.  Oxidative stress is the disruption in the 
balance of antioxidant defenses and reactive oxygen species (ROS) exposure, such that there is 
increased exposure of the cell to ROS.  Reactive oxygen species are formed by the reduction of 
molecular oxygen or the oxidation of water.  Reactive oxygen species include the superoxide anion 
(O2•-), hydrogen peroxide (H2O2), nitric oxide (NO•), peroxynitrite (ONOO-), the hydroxyl radical 
(•OH), and hypochlorous acid (HOCl).  The hydroxyl radical is formed following reaction of H2O2 
with transition metals via the Fenton reaction (as reviewed in Valko et al106).  Reactive oxygen 
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species are important in normal cell signaling.107  However, excessive ROS exposure may result in 
transient or permanent structural modifications within the cell.  Excessive ROS production may be 
due to production by the mitochondrial electron transport chain, or other enzyme systems including 
NADPH oxidase, nitric oxide synthase, or xanthine oxidase.   
In a normal physiologic state, mitochondria are responsible for a majority of the cellular ROS 
production, with 2% of the oxygen delivered to the electron transport chain becoming superoxide.106  
The majority of superoxide production occurs at mitochondrial Complex I (NADH-dehydrogenase) 
and III (cytochrome b/c).108  Impairment of mitochondrial function can have a profound effect on 
ROS production.  Mitochondrial dysfunction may be associated with decreased electron transport 
chain activity109 or decreased mitochondrial density.109,110  Decreased mitochondrial density may be 
due to small size of mitochondria109 or low numbers of mitochondria.110 
Mitochondrial size and copy number are regulated by mitochondrial dynamics and 
mitochondrial biogenesis.  Mitochondrial dynamics is a term used to describe the relationship 
between mitochondrial morphology and function.  In response to changes in cellular environment, 
mitochondria may undergo fission or fusion, and these changes are mediated primarily by GTPases.  
Fission is the process of mitochondrial division without replication of mitochondrial DNA, and is 
primarily mediated by the outer membrane proteins fission 1 (Fis1) and dynamin-related protein 1 
(Drp1).  In contrast, fusion is the joining of mitochondria that allows for DNA recombination, transfer 
of products of metabolism, and rescue of the membrane potential.  Mitochondrial fusion is protective 
against ROS-induced matrix damage.111  Fusion is mediated by the outer membrane proteins, 
mitofusins (Mfn) 1 and 2 and the inner membrane protein, optic atrophy protein 1 (OPA1).  A balance 
between fission and fusion is critical for mitochondrial health.  Excessive fission leads to small, 
fragmented mitochondria, whereas excessive fusion leads to long reticulated mitochondrial 
networks.112 The maintenance of a normal mitochondrial network is important for mitochondrial 
function, and downregulation of Mfn2113 or Fis1114 results in impaired oxidative phosphorylation.  
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Alterations in mitochondrial dynamics are also linked to ROS production.  Hyperglycemia-induced 
mitochondrial ROS production requires mitochondrial fission.115  Type II diabetes has been 
associated with an alteration in regulation of mitochondrial dynamics, with a shift towards 
fission.112,116  In addition to its role in regulating mitochondrial fusion, Mfn2 also has an important 
role in regulation of metabolism, including glucose oxidation, mitochondrial oxidative 
phosphorylation, and insulin signaling.117 
Mitochondrial biogenesis is the process of mitochondrial replication, which is a complex 
process requiring the coordination of assembly of proteins that are nuclear and mitochondrial-
encoded.118   Mitochondrial biogenesis is stimulated by acute increases in ROS.  Mitochondrial 
biogenesis is regulated primarily by the peroxisome proliferator activated receptor coactivators, PGC-
1α and PGC-1β.  PGC-1β is an important regulator during the basal state, while PGC-1α can be 
induced by a number of signals, including increased ROS production.119,120  Downstream of the PGC-
1 co-activators is the estrogen related receptor α (ERRα), nuclear respiratory factor (Nrf) 1 and 2 and 
mitochondrial transcription factor A (TFAM). Estrogen related receptor α is a critical downstream 
regulator of PGC-1α-induced mitochondrial biogenesis.121  The nuclear respiratory factors regulate 
transcription of nuclear oxidative phosphorylation genes. Type II diabetes is associated with a 
reduction in skeletal muscle gene expression of regulators of mitochondrial biogenesis and oxidative 
phosphorylation, including PGC-1α, PGC-1β and Nrf1,122,123 although these changes may in part be 
associated with a sedentary lifestyle.124 
Increased ROS production alone may be insufficient to cause oxidative damage, as cells can 
upregulate antioxidant defense capacity in response to increased ROS.   However, failure of 
antioxidant defenses to upregulate in response to increased ROS, overwhelming ROS production in 
the face of normal antioxidant defenses, or decreased antioxidant capacity may all result in oxidative 
stress.  Within the mitochondria, primary antioxidant enzymes include the superoxide dismutase 
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(SOD), manganese SOD (MnSOD), the peroxiredoxins, and glutathione peroxidase (GPX).125  
Antioxidant defenses within the cytosol neutralize ROS that escape the mitochondria or derive from 
other sources.  Key cytosolic antioxidants include the glutathione system, copper, zinc-SOD and 
catalase. The SODs catalyze the conversion of superoxide to the less reactive H2O2.  The glutathione 
system is responsible for recycling glutathione from oxidized to reduced states, and consists of 
glutathione synthase (GSS), glutathione reductase (GRS), and glutathione peroxidase (GPX).126  
Glutathione synthase is an enzyme important in the creation of glutathione.  Glutathione reductase 
converts oxidized glutathione to reduced glutathione, using NADPH as a cofactor.  Glutathione 
peroxidase oxidizes glutathione in order to reduce H2O2 within the cell.  Normally, the GRS is 
efficient at maintaining large store of reduced glutathione.  Catalase is an antioxidant enzyme found 
in peroxisomes, lysosomes, and mitochondria that converts H2O2 into water.  In people and rats, 
obesity and insulin resistance are associated with both upregulation and depletion of antioxidant 
capacity.127,128  Differences in results may be attributed to severity or chronicity of ROS insult.129 
Once antioxidant defenses are overwhelmed, oxidative damage can occur to DNA, lipids, or 
proteins.  ROS can interact with nuclear or mitochondrial DNA, causing damage including 
modification of bases, breaks or cross linking of DNA, and damage to repair mechanisms.130 
Mitochondrial DNA is more sensitive to ROS-induced damage than nuclear DNA due to poor repair 
mechanisms and absence of protective histones.131  Of the lipid molecules, the polyunsaturated fatty 
acids (PUFAs) are the most sensitive to free radicals.132  Formation of lipid peroxides may alter 
membrane stability and function of membrane-associated proteins.133  Proteins are also susceptible to 
oxidation, by attack of amino acid residues.134 
ROS directly impact insulin signaling through activation of stress kinases, including JNK and 
IKKβ (Figure 2).135  In IR people, ROS activates JNK, which phosphorylates a serine residue on the 
IRS1 protein, impairing downstream signaling.135  ROS can also modulate insulin signaling through 
inhibition of several tyrosine phosphatases, including the protein tyrosine phosphatase 1B (PTP1B) 
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and phosphatase and tensin homologue (PTEN).136  PTP1B dephosphorylates the tyrosine residue on 
the IRS1, while PTEN mediates the conversion of PIP3 to PIP2.  Inhibition of these phosphatases 
results in enhanced downstream signaling.136  Thus, it appears the quantity and location of ROS 
production are important in determining whether insulin signaling is impaired or enhanced.136 
The source of ROS resulting in oxidative stress in obesity and insulin resistance remains a 
matter of debate.  Although initial studies implicated mitochondria as the source of increased cellular 
ROS, recent studies have found evidence that mitochondrial dysfunction is the consequence of 
oxidative stress.137  Whether mitochondrial dysfunction causes oxidative damage or merely 
perpetuates the pro-oxidant state, it is clear that impaired mitochondrial function occurs in association 
with obesity and insulin resistance in people.138 
Evaluation of the role of oxidative stress in equine obesity and IR remains limited to studies 
of systemic oxidative stress.  No relationship between systemic markers of oxidative damage or 






Figure 2.  Interaction of ROS with normal insulin signaling pathway.  Reactive oxygen species 
activate the stress kinases, c-Jun N-terminal kinase (JNK) and inhibitor of nuclear factor kappa B 
kinase β (IKKβ) through inhibitory phosphorylation of IRS1, impairing insulin signaling.  ROS also 
enhance insulin signaling through inhibition of the phosphatases, phosphatase and tensin homologue 
(PTEN) and protein tyrosine phosphatase 1B (PTP1B).   See Figure 1 for remainder of key.
	   	  




































Measurement of mitochondrial function and oxidative stress 
 Mitochondrial function may be directly assessed through measurement of individual complex 
activity, ATP synthesis, or by respirometry, either within cells or within isolated mitochondria.141  
Direct measurement of mitochondrial function is technically challenging, thus, surrogate markers of 
function, including evaluation of mitochondrial biogenesis and mitochondrial dynamics, are 
commonly employed.141  
Quantification of oxidative stress within a biological system can be challenging, due to rapid 
metabolism in vivo and influence of ex vivo factors on stability of markers of oxidative stress.  
Oxidative stress may be quantified by direct measurement of free radical formation, or indirectly 
through assessment of antioxidant capacity or markers of oxidative damage.  Due to the challenges in 
obtaining results representative of cellular oxidant status with any single method, it is prudent to 
measure multiple markers in order to determine cellular oxidant status. 
 Free radicals may be directly measured by electron spin resonance spectroscopy, spin 
trapping, or use of fluorescent or chemiluminescent probes.142,143  Assays of free radical formation are 
expensive and technically difficult to perform.  Therefore, measurement of antioxidant capacity and 
oxidative damage are often undertaken to evaluate the effect of increased ROS.  Antioxidant capacity 
may be assessed through measurement total antioxidant capacity or by measurement of individual 
antioxidant content or enzymatic activity.134 
Markers of oxidative damage include oxidized DNA,144 lipids,132,134 or proteins.145,146 Markers 
of lipid peroxidation can be difficult to quantify, as they are predisposed to ex vivo degradation or 
formation.132,134  Markers of protein oxidation include tyrosine oxidation products and carbonylated 
proteins.146  Oxidized proteins are typically more stable than oxidized lipids, and perhaps are a better 
indicator of chronic oxidative stress.145  However, in states characterized by intracellular lipid 
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accumulation, such as obesity-associated IR, measurement of lipid peroxides may be more indicative 
of cellular oxidative damage.147 
Mechanisms of obesity-associated IR: Inflammation  
A pro-inflammatory state exists in people with obesity-associated insulin resistance.148  
Systemic inflammation is strongly associated with obesity and regional (visceral) adiposity149-151	  and 
a risk of development of type II diabetes.152 The chronic pro-inflammatory state identified within 
circulation of obese people is characterized by increased circulating concentrations of TNFα, IL1β, 
IL6 and the acute phase proteins, serum amyloid A (SAA) and C reactive protein (CRP).149,151,153,154 
It has been proposed that these inflammatory signaling molecules act in an autocrine, 
paracrine, or endocrine fashion to promote additional pro-inflammatory cytokine production and 
impair insulin signaling in insulin sensitive tissues.155  TNFα can bind to cellular receptors and 
activate intracellular stress kinases, including c-Jun-N terminal kinase (JNK) and inhibitor of nuclear 
factor kappa B kinase β (IKKβ).  These stress kinases activate transcription of additional 
inflammatory cytokines in insulin-sensitive tissues.  Furthermore, stress kinases impair insulin 
signaling by causing serine (inhibitory) phosphorylation of the IRS1 protein and inhibitory 
phosphorylation of the AS160 (Figures 2 and 3).156  
The sources of circulating inflammatory cytokines remains under investigation, but both 
adipose and skeletal muscle are characterized by a pro-inflammatory state in obesity.  Increased gene 
expression and protein secretion of TNFα was first identified in adipose tissue of obese mice.157  
These findings were later confirmed in adipose explants of obese people.158  Although initial evidence 
suggested that adipocytes were the primary source of inflammatory cytokines in white adipose tissue 
(WAT),157 more recent data suggests that it is primarily the non-adipocyte fraction (stromal-vascular 
cells and macrophages) that creates an inflammatory state within WAT.159  The interplay between 
adipocytes and macrophages is important, as adipocytes secrete MCP-1 which promotes macrophage 
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infiltration of adipose tissue.160,161	  	  Macrophages secrete inflammatory cytokines and stimulate 
inflammatory cytokine expression by adipocytes. In WAT, cytokine expression varies with fat depot 
location.  Visceral adipose is generally considered to be more pro-inflammatory than subcutaneous 
adipose, a difference which appears to be attributable to the vascular fraction.162,163  Increased 
concentrations of TNF-α have also been demonstrated in skeletal muscle of obese, IR people, 
although whether this is a primary event or subsequent to systemic or adipose inflammation is 
unclear.164,165   
In horses, systemic inflammation has not been strongly associated with obesity or insulin 
resistance when accounting for age.19,139,140,166-169  Investigations of tissue inflammation in horses have 
been limited to comparisons between overconditioned IR and IS horses, without stratification by 
obesity.77,170 Pro-inflammatory gene expression, including expression of MCP-1, was not different 
between IR and IS horses in visceral or subcutaneous adipose depots.77  Evaluation of TNFα protein 
content yielded variable results based on the tissue examined; TNFα was increased in visceral 
adipose, but not nuchal adipose or skeletal muscle of IR compared to IS horses.170  These early 
findings suggest that in horses, WAT inflammation varies by location, and visceral adipose 






Figure 3.  Inflammatory cytokines activate pathways to increase inflammatory cytokine 
transcription and impair insulin signaling.  TNFα = tumor necrosis factor α.  TNFR = Tumor necrosis 
factor receptor.  IκK = inhibitor of nuclear factor kappa B kinase.  NF-κB = nuclear factor kappa B.  




Mechanisms of obesity-associated IR: lipotoxicity 
Obese humans have impaired free fatty acid (FFA) metabolism manifested by increased 
circulating FFA concentrations, increased lipolysis, and reduced suppression of FFA turnover by 
insulin.171,172  High circulating concentrations of FFAs trigger intramyocellular accumulation of fatty 
acids, primarily as di-, or triacylglycerol, long-chain fatty acyl-CoA, or ceramides.  Cytosolic 
accumulation of free fatty acids has several effects on glucose metabolism.  Di- and triacylglycerol 
activate protein kinase C θ, which causes serine (inhibitory) phosphorylation of IRS1.173,174  Increased 
cellular FFAs may impair glucose oxidation by inhibiting pyruvate dehydrogenase.175  Accumulation 
of fatty acid metabolites inhibits import of long chain fatty acids into the mitochondria176 and impairs 
electron transport chain activity.177  Plasma free fatty acids downregulate the expression of oxidative 
phosphorylation genes.178  Although intramyocellular lipid accumulation is recognized to be 
associated with insulin resistance in human obesity, endurance athletes have increased intracellular 
lipid accumulation compared to non-obese, sedentary adults yet are highly insulin sensitive.179  This 
finding is referred to as the “athlete’s paradox.”180  Although the reason for the differences in 
consequences between lipid accumulation in obese people and accumulation in athletes is not known, 
it may be associated with type of lipid179 or degree of lipid peroxidation.181 
Measurement of serum insulin concentrations in the horse 
Accuracy in measuring serum insulin concentrations is important for assessing insulin 
sensitivity in equids.  Equine insulin (molecular weight, 5748 Da) has two amino acid substitutions 
which differ from human insulin (molecular weight, 5808).182  One of these substitutions, amino acid 
30 (threonine in humans, alanine in horses), exists in a location that may affect three dimensional 
structure of insulin, thus potentially impacting equine insulin binding in a human assay.183  Multiple 
assays have been employed to assess equine serum insulin concentrations, including the 
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radioimmunoassay (RIA)a and the ELISAb,184  The RIA is a competitive antigen binding assay using 
radioactive (I125) insulin.  Both the RIA185 and the ELISA186 have been validated in the horse.  
However, both the RIA and the ELISA substantially and consistently underestimate insulin 
concentration when compared to liquid chromatography-mass spectrometry.184  Comparison between 
the RIA and the ELISA revealed poor agreement at high concentrations of insulin.183 
The RIA is the most commonly used assay for measurement of equine insulin.  However, it is 
an inconvenient assay, requiring overnight incubation.  Furthermore, it requires special equipment 
and handling of radioactive isotopes.  An assay which requires less technical expertise and improved 
accuracy in detection of equine insulin is desirable. 
The Immulitec measures serum insulin by a chemiluminescent immunometric sandwich assay 
(CIA), using a mouse monoclonal capture antibody and a mouse monoclonal and sheep polyclonal 
detecting antibody.187 This technique offers several advantages over the RIA in that it is performed 
quickly, requires little technical expertise, and does not require use of a radioactive isotope.  The CIA 
has been recently used in horses to evaluate response to therapy.188  However, to the author’s 
knowledge, this method has not been validated in the horse.   
Summary and Hypotheses 
There is increasing recognition of equine obesity, insulin resistance or hyperinsulinemia, and 
equine metabolic syndrome (EMS).  The mechanisms leading to the development of obesity-
associated IR in horses have not been determined.  Accurate assessment of insulin dysregulation and 
identification of mechanisms leading to IR are paramount for the development of preventative 
measures and treatments. 
In order to improve understanding of the mechanisms leading to EMS, we developed the 
following central hypothesis:  Impaired insulin signaling within skeletal  muscle causes 
equine insulin resistance.  
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 To test this hypothesis, an accurate method for measurement of equine serum insulin is 
required.  Radioimmunoassay (RIA) is a commonly employed method of measuring equine insulin 
within a research setting.  However, it is an inconvenient assay requiring overnight incubation and 
handling of radioactive isotopes.  Therefore, we sought to evaluate a more convenient, automated 
assay: the chemiluminescent immunometric assay (CIA).  We hypothesized that the CIA 
offers improved detection of equine insulin compared to the RIA.   To address this 
hypothesis, the following specific aims were constructed: 
Specific Aim 1:  To validate the chemiluminescent immunometric assay.  For validation of the assay, 
linearity, recovery, and inter-assay precision were determined. 
Specific Aim 2:  To compare the CIA to the RIA.  To assess this aim, insulin was measured by both 
methods in 40 equine serum samples. 
 Next, three specific hypotheses were developed to evaluate the role of skeletal muscle insulin 
resistance in EMS. 
Hypothesis 1: The hyperinsulinemic euglycemic clamp yields comparable results to the oral sugar 
test and the insulin response to dexamethasone test.   
Specific Aim:  To determine the relationship between insulin sensitivity indices obtained by the HEC, 
OST, and IRDT.  To achieve this aim, the insulin sensitivity index obtained by the HEC was 
compared to the insulin and glucose response of the OST and the insulin response of the IRDT. 
Hypothesis 2:  Skeletal muscle oxidative stress causes equine insulin resistance. 
Specific Aim: To evaluate the role of skeletal muscle oxidative stress in IR.  To assess this aim, 
markers of mitochondrial function, antioxidant capacity, and oxidative damage within skeletal muscle 
were quantified in insulin sensitive and insulin resistant horses. 
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Hypothesis 3:  Skeletal muscle inflammation causes equine insulin resistance. 
Specific Aim 3:  To characterize skeletal muscle and systemic inflammatory state of insulin resistant 
and insulin sensitive horses.  For evaluation of this specific aim, markers of systemic and skeletal 
muscle inflammation were measured. 
Footnotes 
aCoat-A-Count, Siemens, Tarrytown, NY 
bMercodia, Uppsala, Sweden 







REVIEW OF IMMMUNOASSAY VALIDATION FOR THE VETERINARY CLINICIAN 
 
INTRODUCTION 
In order to accurately identify disease, it is critical that testing protocols and laboratory 
assays be appropriately validated.  Furthermore, it is important to standardize across assay 
methodologies in order to allow for comparison between laboratories or studies.  The purpose of 
this paper is to review laboratory assay standardization and cross-validation of methodologies, 
using an example of cross-validation of two commercially available methodologies, a 
chemiluminescent immunometric assaya (CIA) and a radioimmunoassayb (RIA) for determining 
equine insulin concentrations. Recent guidelines from the American College of Veterinary 
Clinical Pathology189 were used as a reference during assay validation.  
REVIEW OF ASSAY VALIDATION 
Assay validation should include evaluation of accuracy, linearity, analytical range, 
precision, lower limit of detection, functional sensitivity, and effects of commonly encountered 
substances.189 Accuracy is the closeness of agreement between the measured value and actual 
concentration of the analyte.189 Precision refers to the reproducibility of the method. Development 
of an immunoassay requires determination of the working range, accuracy, intra- and inter-assay 
precision, interference, and recovery.190  If possible, the new method should be compared to a 
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reference method to evaluate systematic error (or bias) of the new method.191  For an assay to be 
meaningful, there must be a consistent, proportional relationship between analyte concentration and 
signal.192  This relationship is defined as linearity, and is an important component to determination of 
accuracy and analytical range. To determine linearity, a standard curve must be developed with at 
least six standards in an appropriate matrix.193 Standards should have concentrations spanning the 
expected working range.193  Furthermore, sample linearity must be assessed from a high concentration 
to a low concentration.  This will also allow for estimation of the lower limit of quantification in 
biological samples,193 and will determine whether dilution is required for samples to enter the 
working range.  Linearity should be assessed in a series of 5 dilutions using aliquots of varying 
concentrations of a sample with low concentration of analyte (low pooled) and high concentration 
(high pooled) of analyte.189  Linearity is determined to exist if mean accuracy is 70-130% compared 
to undiluted sample and CV ≤ 25%.193  For sample dilutions, a solution should be used that 
approximates real sample matrix.189   
Recovery is a measurement of selectivity of the assay in the presence of endogenous matrix 
components.193 It is a reflection of accuracy of the method.  Recovery should be assessed in a sample 
of high concentration, or, if necessary, a sample that has been spiked with a standard with high 
concentration of analyte.189  If a standard solution is to be added to the sample to evaluate recovery, 
dilution of the sample by the standard should not exceed 10% so as not to substantially alter sample 
matrix.189  Recovery studies should cover the expected range of analyte values in patient samples.189 
For immunoassays, recovery is considered adequate if accuracy is 70-130% compared to unspiked 
sample and CV ≤25%.193 
Specificity is another important component of accuracy.  For antibodies, specificity should be 
tested by evaluating three samples spiked with a protein that belongs to the same family or has similar 
structure to the target biomarker.  Specificity should be assessed at a physiologic concentration and at 
a supraphysiologic (100-fold) concentration.193 
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Precision is a measurement of random error that is determined by measurement of coefficient 
of variation (CV).194 Coefficient of variation (CV) is calculated using the following formula:195 
% CV = (standard deviation/mean) *100 
Precision should be defined in two ways, by measurement of the same sample within a single 
run of the assay (intra-assay CV) and by measurement of the same sample on separate runs (inter-
assay CV).  Precision should be evaluated by measurement of 20 replicates of at least 3 samples 
spanning the expected analytical range (i.e., low, medium, and high concentration).189  Ideally, inter-
assay CV should be performed at least 24 hours apart and should be assessed over 20 days.190  Inter-
assay variation should be performed on aliquots to eliminate the effects of repeated freeze/thaw 
cycles.189  Intra- and inter-assay CVs should be <25%.193 
Limit of detection and functional sensitivity should be established by using a series of low 
spiked samples and a blank sample.189 Lower limit of detection is considered to be the mean of the 
blank plus 2 or 3 standard deviations of the blank,189  and determines when analytical noise associated 
with the blank interferes with reliable detection of the analyte.192  Functional sensitivity is the mean of 
the lowest spiked sample that has a coefficient of variation of ≤20%.189  This measurement is used to 
determine imprecision at low analyte levels.196  The coefficient of variation typically increases as 
analyte concentrations approach the lower limit of detection, and a concentration with a CV of 20% is 
considered to be at the limit of useful measurement.189 
The effect of commonly encountered interfering substances should also be considered.189  
Common interfering substances in serum or plasma assays include bilirubin, hemoglobin, and 
lipids.197  Interfering substances may falsely increase or decrease test results.  When analyzing the 
effect of interfering substances, it is important to use concentrations that are within expected range of 
concentration in patient samples.189  The volume of interfering substance added should be minimized 
in order to maintain the properties of the sample matrix.189 
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To compare the new method to a previously validated, established method, it is recommended 
that at least 40 samples with analyte concentrations covering the entire working range of the assay be 
measured in duplicate.189  When diagnostic tests are to be used with samples with a low range ratio 
(i.e., expected maximum value and minimum value of analyte are close together), more than 40 
samples may need to be included to achieve adequate statistical power.194 Diagnostic test comparison 
should be conducted over several days or weeks.  Creation of a difference plot (Bland-Altman) and 
calculation of total error should be performed using the following equation:189  
TE = Biasmeas + 3 * CV 
Bias can be determined from Bland-Altman analysis, and is a measure of systematic error.189  
Systematic error is the difference between the new method’s measurement of the analyte and the true 
value, as determined by an established reference method.194  Coefficient of variation is a measurement 
of random error.  For this equation, CV is determined from the inter-assay repeatability experiment.191  
This calculated total error should be less than the established total allowable error for the initial test.  
Total allowable error is dependent upon biologic variation of the assay and rate of inappropriate 
categorization (e.g., normoinsulinemic horse being categorized as hyperinsulinemic). 
Relationships between the two test methods should be further evaluated using correlation 
analysis.  If correlation between the two methods is <0.975 for data with a narrow range or <0.99 for 
data with a broad range, data may be improved through increasing sample size or replicates.194  
Alternative statistical methods for regression should be employed if correlation is not improved with 
additional samples.194	  	  However, if the correlation coefficient is considerably lower, then the two tests 
are unlikely to be interchangeable.198 
If correlation is ≥0.975 or ≥0.99, respectively, linear regression can be used to estimate 
bias.194  Linear regression may also be used to determine whether constant or proportional systematic 
errors are present.  Constant error is interpreted on the basis of intercept (constant error present if 
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intercept ≠0), and proportional error is interpreted by slope (a slope≠1 indicates presence of 
proportional error).198  If no proportional error exists, data may be analyzed for agreement using a 
concordance coefficient.199  If proportional error exists, alternative linear regression should be used. 
The clinical importance of proportional or constant error is reflected by determination of bias and 
total error;200 however, significant systematic error of any type likely indicates that the methods 
should not be used interchangeably. 
For clinical application of an assay, it is not only important to determine agreement with an 
established method but also diagnostic consequences of disagreement.201  Disagreement with 
consequences as to clinical decision making (such as defining a horse as normoinsulinemic or 
hyperinsulinemic) may be defined as a discordance rate.201 Discordance may be defined as a fraction 
of the total study group using the following equation:202 
Unefficiency = (fp+fn)/(fp+fn+tp+tn) 
In this equation, a false positive (fp) is defined as a difference between assays whereby the 
value from new assay is above and the reference assay is below the decision-making point for disease.  
A false negative (fn) exists when the value from the new assay is below and the reference assay above 
the cutoff for clinical decision making.  True positives (tp) exist when measurements from both 
assays are above the cutoff value, and true negatives (tn) where both assays are below the cutoff 
value. 
METHODS FOR MEASUREMENT OF EQUINE INSULIN 
With increasing recognition of equine insulin resistance and its complications,9 there is a 
demand for convenient, accurate tests for measurement of equine insulin.  In addition to the RIA that 
has been validated for use in the horse,203 several additional methods of measurement have been 
evaluated for equine use, including an additional RIA and four ELISAs.184  An equine ELISA 
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validated in the horse, but the assay had poor concordance with the previously validated RIA.184  
Furthermore, the ELISA demonstrated poor concordance while the RIA had moderate concordance 
with liquid chromatography/mass spectrometry; both assays consistently underestimating plasma 
insulin concentrations.184  These findings suggest that accurate measurement of equine insulin is not 
currently achieved using commercially available assays.  Determination of agreement between insulin 
assays is an important issue to be addressed.  Once agreement is evaluated, a method for 
standardization or harmonization of equine insulin assays will allow for consistent identification of 
insulin concentrations of horses in clinical and research settings.  In people, initial recognition of poor 
agreement between insulin assays led to harmonization of assays and substantial improvement in 
method agreement.204 
The chemiluminescent immunoassay is a convenient method of equine insulin measurement 
that has been used to assess response of insulin resistant horses to therapy.56  However, to the authors’ 
knowledge, this method has not yet been validated in the horse.  Therefore, the purpose of this study 
was to validate the CIA and compare the CIA to the previously validated RIA.  
ASSAY VALIDATION: MEASUREMENT OF EQUINE INSULIN USING THE 
CHEMILUMINESCENT ASSAY AND COMPARISON TO THE RADIOIMMUNOASSAY 
Materials and Methods 
Archived serum from 40 horses was used for measurement of serum insulin.  Serum had been 
stored at -80°C until analysis, and all analysis was undertaken within 6 months of sample collection. 
Linearity 
 Linearity of the CIA was determined using equine serum-based control solutions at four 
insulin concentrations from 0-320 µIU/mL.  Dilutional parallelism was evaluated in a high 
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endogenous insulin equine serum (measured concentration using CIA was 111 µIU/ml) using both the 
RIA and CIA. 
Recovery 
 A commercially available equine insulin standardc was used to determine recovery.  Two 
different equine serum samples with low (<7 µIU/mL) serum insulin were spiked with the 
commercially available equine standard (12 ng/ml) and serially diluted with the low endogenous 
insulin serum to achieve concentrations of 75 µIU/mL, 37.5 µIU/mL, 18.8 µIU/mL, and 9.4 µIU/mL. 
Intra-assay coefficient of variation 
Intra-assay coefficient of variation was determined on the CIA with two equine serum-based 
control solutions, one at low and one at medium concentrations. As all samples were evaluated in 
duplicate with the RIA, intra-assay coefficient of variation was evaluated for all 40 serum samples. 
Inter-assay coefficient of variation 
Inter-assay coefficient was performed in three pooled samples, high (mean, 134.2 µIU/mL), 
medium (mean, 24.4 µIU/mL), low (2.3 µIU/mL) and on the provided medium (mean, 11.53 
µIU/mL) and high (mean, 59.3 µIU/mL) equine serum-based control solutions.  Six replicates of 
controls, four replicates of medium pooled serum, and five replicates of high and low serum were 
evaluated. 
Comparison of methods 
Two commercially available assays for measuring insulin were used, the RIA and CIA.  The 
RIA has been previously validated203 for use in horses.  Forty serum samples with insulin 
concentrations that were expected to vary over a wide range were measured with RIA and CIA.  
Samples evaluated by RIA were measured in duplicate. 
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Treatment of discordant samples 
Samples from 5/40 horses were found to be discordant between methods, using the 
previously recommended concentration of 20 µIU45 as the level of clinical decision making.  All five 
of these horses had higher insulin values on the CIA.  Two of these horses underwent repeated 
sampling over a four-month period, during a fasted state or an oral glucose challenge. Six of eight 
samples from Horse 1, and 4/4 samples from Horse 2 were discordant.  Discordant results occurred 
during fasting and following an oral glucose challenge.  Two samples that were discordant between 
the RIA and CIA and were further evaluated subsequent to polyethylene glycol (PEG) treatment, as 
previously described for displacement of antibodies.205,206 Samples were treated with an equal volume 
PEG 6000 solution (250 g/L PEG in 0.05 mmol/L phosphate buffer, pH 7.4, containing 0.5 g/L Triton 
X-100).  The solution was vortexed and allowed to sit at room temperature for 20 minutes followed 
by a 15 minute centrifugation at 1200 g.  The supernatant was decanted and used for analysis. 
In addition, in order to determine if discordance was related to recognition of a substance 
other than insulin within the equine matrix, human recombinant insulind was used to spike a low 
serum sample, and recovery was assessed. 
Statistical Analysis 
 Linearity and dilutional parallelism were assessed by linear regression and determination of a 
best fit line.  A Pearson’s correlation coefficient was calculated for the 40 samples analyzed by both 
methods.  Deming’s regression was performed to evaluate the relationship between the RIA and CIA.  
A Bland-Altman difference plot was created and a paired t-test was used to calculate bias.  
RESULTS 
 Linearity using equine-serum based control solutions was excellent (r2=0.99, p<0.001) 
(Figure 4).  Dilution of a high endogenous insulin (96 µIU/mL) sample indicated a strong relationship 
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between expected concentrations of the diluted sample and measured concentrations from both assays 
(RIA, r2=0.99, p<0.001, CIA, r2=0.92, p=0.009, Figure 5). 
Recovery of the equine insulin standard using both the RIA (53.8±3.9%) and the CIA 
(8.4±2.1%) was poor (Figure 6). When evaluating precision of the CIA, intra-assay CV of the low 
(10.44 µIU/mL) and high (55.40 µIU/mL) equine-serum based control solutions was 2.5% and 3.1%, 
respectively, while inter-assay CV was 13.7% and 5.5%, respectively.  The pooled equine serum 
samples had inter-assay CV of 30% (medium) and 4.1% (high).  The low pooled sample was not 
included in analysis as 4/5 readings were below detection. 
Additional determination of the validity of the CIA was performed by cross-referencing to the 
commonly used RIA.  Insulin concentrations of forty samples ranged from <3.5-215.6 µIU/mL 
(median, 11.54) using the RIA and <2-224 µIU/mL (median, 11.9) using the CIA. Correlation 
analysis between the two assays revealed good correlation (r=0.58, p<0.001).  Regression analysis 
yielded a best-fit line of y=1.81x -5.06 (Figure 7).  There was no significant difference between the 
CIA and RIA measurements (p=0.81).  However, a bias did exist, with the CIA an average of 12.7 
µIU/mL higher than the RIA (95% limits of agreement, -70.9 to 96.9, Figure 8). The bias was due to 
proportional error (95% limits of agreement for slope, 1.04-2.58; 95% limits of agreement for y-
intercept, -37.7 to 27.6).  Total error was 63.1%. The bias was primarily associated with 5 discordant 
samples; removal of these samples from analysis yielded a bias of 1.5 µIU/mL (95% limits of 
agreement, -16.6 to 19.5).  However, even with exclusion of these five samples, assay performance 
exhibited a total error of 51.9%. 
Due to the discordance between the CIA and RIA, investigations were undertaken to try to 
determine possible reasons for method discordance.  Discordance in measurement may be associated 
with substances that interfere in one assay but not another, including bilirubin, hemoglobin, lipids, 
antibodies, or other proteins.  As visual inspection did not reveal the presence of interfering pigments 
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or lipids, the possibility of interference by antibodies (heterophilic or anti-insulin) was evaluated by 
treatment of discordant samples with polyethylene glycol (PEG).  Polyethylene glycol allows for 
displacement of antibodies from solution, decreasing antibody interference with the assay.206  
Treatment with PEG did not significantly alter serum insulin concentrations of 2 discordant samples 
(p=0.07; Table 1).  In addition to PEG treatment, serial dilution of an equine serum sample with 
added non-equine insulin (human recombinant insulin) was performed to determine if discordant 
results were a result of an intrinsic component of the equine matrix.  Serial dilution of an equine 





















































Figure 4.  Linearity of the equine serum-based control solutions measured by CIA with best-fit line 









Figure 5.  Dilution of a high endogenous insulin serum sample using a pooled low serum sample 
measured by RIA (filled circles) and CIA (open triangles).  Line indicates expected dilution.  Best fit 






















































Figure 6. Recovery of equine insulin standard with the RIA (filled circles) and CIA (open triangles).  







Figure 7. Scatterplot of RIA compared to CIA results.  Deming’s regression analysis indicates a best-


























































Figure 8.  a) Bland-Altman plot of average compared to difference CIA minus RIA. b) Bland-Altman 














Table 1.  Serum insulin concentrations (µIU/mL) before and after polyethylene glycol treatment. 
 CIA CIA PEG RIA RIA PEG 
Horse 1 120 159.6 5.8 6.8 





Equine insulin is commonly evaluated by RIA in research studies.  However, this assay 
consistently underestimates equine insulin concentrations, when compared to LC-MS.184  Although 
mammalian insulins demonstrate substantial homology, equine insulin does differ from porcine, 
human, and bovine insulin by 1-3 amino acids.182  These substitutions may affect insulin binding due 
to different secondary, tertiary, or quaternary protein structure.207,208  Therefore, depending upon the 
amino acid sequence recognized by antibodies in different immunoassays, commercially available 
insulin assays may vary in detection of equine insulin.  This was recently confirmed in an evaluation 
of six different commercially available insulin assays in comparison to LC/MS.184 An accurate, quick 
method for measuring serum insulin in the horse remains to be identified. The CIA performs well in 
people, with 95% of samples falling within 32% total error204 allowed for insulin assays.209 However, 
despite being in use in clinical equine practice,188 the CIA has not yet been validated for use in horses. 
Recovery was poor in both assays, but much worse (average <10%) when using the CIA.    
Poor recovery of equine insulin using commercially available assays has been previously reported,184 
and may be a product of decreased binding of assay antibodies to equine insulin compared to human 
insulin.  The observation that the linearity of the CIA was excellent when using provided equine-
serum based control solutions, but deteriorated when using a high endogenous insulin equine serum, 
would support this explanation. It is also possible that the equine insulin standard had an actual 
concentration that was lower than the labeled concentration, leading to a lower than expected 
recovery.  A role of the equine insulin standard in poor recovery is supported by the observation of 
lower than expected concentrations of the standard in both assays. Inter-assay CIA CVs were more 
variable using pooled equine serum samples, compared to the provided control solutions.  Poor 
recovery and high inter-assay variability on pooled serum samples suggest that the CIA would not be 
an acceptable method of insulin measurement in the horse.   
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Additional evaluation of the CIA included comparison to the commonly used RIA.  Poor 
agreement was found between the CIA and RIA assays for measuring equine insulin. For assays 
measuring human insulin, it is recommended that total error not cause more than 12% error in 
appropriate categorization (i.e., within reference range or outside of reference range) for a given 
sample.209  Acceptable measurement bias and total acceptable error are in part determined by 
biological variation of the analyte.  For human insulin assays, within-individual variation has been 
reported to be 21.1%, and within-group variation for healthy individuals has been reported to be 
58%.210  Recommendations for measurement of insulin concentrations in people include a bias < 
15.5%, imprecision < 10.6%, and total analytical error < 32% for a single result at concentrations 
within the reference interval.209 While this allowable error may seem substantial, within the reference 
interval, considerable variation may exist without impacting test interpretation.  For example, a horse 
with an initial insulin measurement of 10 may have a subsequent insulin measurement of 13.2 or 6.8 
µIU/mL and still be considered insulin sensitive.  Although bias of the CIA was within acceptable 
ranges, total error using inter-assay precision exceeded recommendations for insulin immunoassays. 
Much of the bias and wide limit of agreement observed between assays was attributable to 
five samples. When these five horses were removed from analysis, average bias improved to 1.5 
µIU/mL.  Due to the dramatic improvement of agreement with removal of samples from these horses, 
additional analysis was undertaken to determine possible reasons for the discordant results.  Multiple 
samplings from two of these horses yielded repeatable results, with ten samples being discordant and 
two samples being concordant by the two methods.  In all discordant samples, insulin concentrations 
were substantially higher on the CIA.  As common interfering substances (lipids, hemolysis, 
bilirubin) have been previously documented to falsely lower CIA results in people,187 and visual 
inspection of the samples did not indicate lipemia, hyperbilirubinemia, or hemolysis as a likely source 
of interference, the possibility of an effect by heterophilic or anti-animal antibodies was explored.  
Heterophilic antibodies are weak polyspecific antibodies that are either natural idiotypic antibodies or 
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autoantibodies that interfere with antibody binding in immunoassays by a non-competitive 
mechanism.211 Anti-animal antibodies are typically high affinity antibodies against another species 
following exposure to antigens from that species.211  Interestingly, two-site immunometric assays 
appear to be more prone to interference by heterophilic antibodies than antigen binding assays.211  
Although heterophilic and anti-animal antibodies are not commonly reported in animals, exposure of 
horses to other animal-derived antigens (e.g., rodents) seems plausible.   
Multiple methods are available to eliminate the effects of heterophilic or anti-animal 
antibodies, including polyethylene glycol (PEG) treatment,211,212 heat treatment,211,212 or use of 
blocking serum.211  Insulin is heat-sensitive,213 and determining appropriate concentrations of 
blocking serum can be challenging.213 Therefore, in this study, we chose to evaluate the effect of PEG 
treatment on insulin concentrations.  Polyethylene glycol is a synthetic polymer that may be used to 
precipitate proteins from solution.206  In human serum, it has been used to precipitate 
immunoglobulins and immunoglobulin-antigen complexes to improve detection of hormones and 
other analytes.214  Polyethylene glycol treatment decreased serum insulin concentrations by 
approximately 40% in both the RIA and CIA.  Furthermore, assay results remained discordant 
following treatment, suggesting that changes in insulin concentrations were an effect of dilution, 
rather than an effect of decreased interfering antibody.  Demonstration of consistent recovery of a 
human recombinant insulin within a pooled equine serum sample indicates that the CIA recognizes 
insulin within the equine matrix.  Discordant samples may be associated with other matrix 
components other than interfering antibody or may be due to binding to a substance with similar 
structure to insulin.  Additional matrix components that have been reported to interfere with 
immunoassays include complement or lysozyme.211 
In summary, the CIA does not appear to be an acceptable method of measuring equine insulin 
due to poor recovery of an equine insulin standard and high inter-assay coefficient of variation. This 
study highlights the importance of validating and cross-referencing assays prior to implementation 
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into clinical use.  Several aspects of initial assay validation indicated that the CIA would not yield 
acceptable results. Cross-referencing to the RIA allowed for identification of a bias, with the CIA 
tending to measure higher concentrations than the RIA.   Furthermore, cross-referencing allowed for 
identification of discordant samples.  Reasons for the discordant results are unknown, but appear 
unlikely to be due to interference by antibodies. 
Footnotes 
aImmulite 1000, Siemens, Tarrytown, NY 
bCoat-A-Count, Siemens, Tarrytown, NY 
cShibayagi Company, Ishihara, Japan 










Multiple dynamic field tests are used for assessment of equine insulin resistance.  
However, the relationship between markers of glucose homeostasis and insulin disposal obtained 
by different testing protocols is unknown.  We hypothesized that two recently developed field 
tests for evaluation of equine IR, the insulin-response to dexamethasone test (IRDT) and oral 
sugar test (OST), would yield comparable results to the hyperinsulinemic euglycemic clamp 
(HEC). Fifteen light breed horses with body condition scores of 3/9 to 8/9 were used in this study.  
Eight horses underwent an OST, HEC, and IRDT over a four-week period. The OST was 
performed under two different housing conditions, pasture and stall.  Eight horses underwent an 
OST on pasture three times over a 14-16 week period during the summer and fall.  The HEC did 
not correlate with either the OST or IRDT, but the OST correlated with the IRDT. OST was not 
significantly different when performed in the pasture compared to in a stall, but did change 
significantly over time on pasture.  These results suggest that the OST and IRDT results are not 




Hyperinsulinemia is a recognized risk factor for the development of laminitis.35  In horses 
presenting to a first opinion hospital for evaluation of laminitis, endocrine disorders were the most 
frequently identified cause of laminar disease, with 67% of horses presenting with 
hyperinsulinemia.32  Despite the clinical importance of hyperinsulinemia, there is not an established 
standard for evaluation of glucose homeostasis and insulin disposal in the horse.  Insulin 
dysregulation has been assessed by fasting hyperinsulinemia or proxies,65 and dynamic glucose or 
insulin tolerance testing.76,78,79  In people, the gold standard for evaluation of tissue IR is the 
hyperinsulinemic euglycemic clamp (HEC).67  The HEC has been adapted for use in equids, including 
ponies,68 Warmbloods,68 Belgian horses,70 Standardbreds,71 and Quarter Horses.69,73,215  The HEC is 
ideal for assessing tissue insulin sensitivity, as it eliminates the impact of pancreatic insulin secretion 
or enteral glucose absorption on glucose homeostasis.  However, the HEC technique requires the use 
of infusion pumps and frequent monitoring and thus is not amenable to field testing of client horses or 
epidemiological studies.  Furthermore, the specificity of the HEC for IR within insulin-sensitive 
tissues may be a disadvantage in cases where enteral glucose absorption or pancreatic response to 
glucose may be altered. 
Several tests have recently been developed or adapted for use to improve ease of detection of 
equine insulin dysregulation by practitioners. The oral sugar test (OST) is an oral glucose challenge 
test that was developed for use in the field.49 The simplicity of this test makes it an attractive 
possibility for ambulatory practice.  However, as the response to an oral glucose challenge is 
influenced by enteral glucose absorption, pancreatic insulin secretion, and tissue insulin sensitivity, 
results may differ from the HEC. 
Initial evaluation of the usefulness of the OST in detecting alterations of insulin regulation 
and glucose homeostasis was performed in a controlled environment (stalls).  Despite being in a 
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controlled environment, substantial day-to-day variation in insulin response was observed in a small 
population of horses undergoing repeated measurements (area under the curve for insulin coefficient 
of variation=45%).94  It is uncertain how this test performs when horses are on pasture, which may 
introduce greater variability due to amount of grass consumed and non-structural carbohydrate (NSC) 
content of pasture.  Finally, in horses normally kept on pasture, altering housing may induce stress 
and influence test results.  Thus, it is important to understand how environment impacts test results. 
The dexamethasone suppression test (DST) has historically been used to identify pituitary 
pars intermedia dysfunction.81  Recently, the response to dexamethasone was evaluated as a dynamic 
test of insulin sensitivity. Laminitic, IR ponies were found to have higher insulin concentration post-
dexamethasone compared to control ponies.82  Although these initial findings are promising, these test 
results have not yet been replicated in horses or IR non-laminitic ponies.  
The purpose of this study was to compare three different methods of insulin sensitivity testing 
in Quarter Horses:  HEC, OST, and the insulin response to dexamethasone test (IRDT) (Experiment 
1).  We hypothesized that the HEC, OST and IRDT would correlate well.    A second objective was to 
evaluate the effect of season on the OST in horses maintained on pasture (Experiment 2). 
MATERIALS AND METHODS 
Experiment 1: Comparison of Hyperinsulinemic Euglycemic Clamp, Oral Sugar Test, and Insulin 
Response to Dexamethasone Test 
Horses 
Eight Quarter Horses, aged 7-14 years and weighing 518-645 kg were used in this study.  
There were 7 geldings and 1 mare.  Body condition score ranged from 4.5-7 (median, 5.8).  Horses 
were free of clinical signs of systemic disease including pituitary pars intermedia dysfunction.  Two 
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horses (BCS 4.5 and 5) had navicular disease.  Horses were housed on pasture with free choice grass 
hay. 
Morphometrics 
Height, length, heart girth, abdominal girth,24 and neck circumference28 were measured as 
previously described.  Body mass index was calculated as previously described.22 
Effect of Environment on OST 
To evaluate the effect of environment on OST results, OST was performed as previously 
described.49  All OSTs were performed during a 4 week period between mid-October and mid-
November and initiated between 11 am-12 pm to minimize potential seasonal and diurnal variation in 
glucose and insulin response due to changes in pasture non-structural carbohydrate (NSC) content.  
The order of the OSTs was randomized, with 4 horses undergoing an OST on pasture first and 4 
horses undergoing an OST in a stall first.  OST pasture and OST stall for each horse was performed 
24 hours apart.  Horses undergoing OST stall were fasted for 12 hours (no hay) prior to initiation of 
the OST.  Horses were weighed using an electronic scale on the day of testing.  Blood samples were 
collected at baseline and 75 minutes after the administration of Karoa syrup (0.15 ml/kg, PO).  
Immediate analysis of blood glucose was performed by hand-held glucometerb that has been 
previously validated in the horse216 and was independently validated by the investigators.  Additional 
blood samples were placed on ice until centrifuged.  Serum was stored at -80°C for analysis of insulin 
concentration by radioimmunoassay.c,203  Horses were considered to be insulin sensitive if fasting 
(T0i) and T75i were <60 µIU/mL.49 
Dynamic Insulin Sensitivity Testing 
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Over a four-week period, all horses underwent an OST while stalled (OST stall), HEC, and 
IRDT.  The HEC was performed 36-48 hours after the last OST.  All horses were given at least a 
seven-day washout period between the IRDT and any other dynamic test. 
Hyperinsulinemic Euglycemic Clamp 
The HEC was performed as previously described.	  71  Following a 24-48 hour stall acclimation 
period, intravenous catheters were placed.  Intravenous catheters were placed at least 12 hours prior to 
initiation of the clamp.  Horses were weighed the morning of the clamp.  Insulin was prepared in 
0.9% saline (100 mU/mL using 2 mL of homologous serum).  Baseline blood samples were taken 
prior to initiation of the clamp for immediate analysis of blood glucose using a hand-held 
glucometer.b  Whole blood was saved on ice for evaluation of insulin concentration. A constant rate 
infusion of insulin (3 mU/kg/min) was then initiated with infusion of 50% dextrose used to maintain 
euglycemia.69-71,215  Blood glucose was monitored every ten minutes.  Target blood glucose 
concentration was 99 mg/dL.  Serum was saved for subsequent analysis of insulin concentrations by 
chemiluminescent immunoassay.d  The first 90 minutes were used as an equilibration period.  Once a 
steady-state of euglycemia was achieved, serum glucose and insulin concentrations from a 30 minute 
period were used to calculate the amount of glucose metabolized (M) and insulin concentration (I). 
Insulin response to dexamethasone test 
Analysis of insulin response to dexamethasone administration was performed as described.82  
A blood sample was obtained at 4 pm for assessment of serum insulin concentration.  Dexamethasone 





Correlation coefficients were calculated to evaluate the relationship between BCS, 
morphometrics, and results of dynamic tests.  The blood glucose (T75g) and insulin (T75i) 
concentrations 75 minutes after initiation of the OST for the OST pasture and OST stall were 
compared by a paired t-test to determine repeatability.  As the OST results in the pasture did not differ 
from that in the stall, only the results of the OST stall were used for additional comparison to the 
HEC, and IRDT.   For comparisons of insulin sensitivity status, the M:I ratio (HEC), T0 and T75 
insulin and glucose concentrations (OST) and 19-hr post dexamethasone insulin concentrations 
(IRDT) were compared using a Spearman rank coefficient of correlation. 
Experiment 2: Seasonal variation of the OST 
Horses 
Horses used in this study were aged 8-23 years.  Body condition score ranged from 3-8 
(median, 5).  There were two Arabian mares, five Quarter Horses (two geldings and three mares), and 
one Thoroughbred gelding.  Horses were housed on pasture with free choice grass hay.  The three 
Quarter Horse mares were supplemented with 2.5 pounds of grain once daily.  Horses underwent 
OSTs (as described above) three times, once between June 8 - July 10 (OST Summer) and twice in 
fall (OST September and OST October).  Blood glucose and serum insulin concentrations were 
measured at baseline and 75 minutes after the administration of Karo syrup as described above. 
Statistics 
Analysis of variance for repeated measures was used to evaluate the effect of time (month) on 
fasting insulin concentration, T75i and T75g.  Bonferroni’s post-hoc correction was applied when 





 Based on OST results, all horses were considered to be insulin sensitive.49  When evaluating 
the relationship between OST stall and OST pasture, there was no significant difference between OST 
T75g (p=0.32), although there was a trend toward a difference in OST T75i (mean difference, 2.7 
µIU/mL; p=0.08; Figure 10).  Due to the similarities between the two tests, the OST stall was used for 
additional comparisons between insulin sensitivity methods.  There was poor correlation between the 
HEC and other tests (Figure 11).  A moderate correlation existed between the IRDT and OST T75i 
(r=0.54), although this relationship failed to reach significance (p=0.16) (Figure 3).  
 Simple correlation analysis revealed a strong correlation between girth and other assessments 
of obesity or body mass (BCS, weight, body mass index, and neck circumference; Table 2).  No index 
of obesity correlated with indices of insulin sensitivity. 
Experiment 2 
 Season had a significant impact on the OST T75g (p=0.02), with the difference attributable to 
the Summer to September interval (p<0.05, Figure 12).  Peak OST insulin (T75i) exhibited a trend 



















































































Figure 10.  Comparison between OST pasture and OST stall: A) OST T75i, B) OST T75 glucose 







Figure 11.  Scatterplot depicting the relationship between dynamic insulin sensitivity test results. a) 
HEC and OST T75 insulin concentration (OST T75i); r=0.31, p=0.46, and b) HEC and IRDT insulin 
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Figure 13.  Differences between OST results across season.  a) OST T0i, b) OST T75i, c) OST T75g. 





Table 2. Coefficients of correlation for indices of obesity and insulin sensitivity for the HEC, IRDT, 
and stall OST. BMI = body mass index.  M = rate of glucose metabolism.  M:I = rate of glucose 
metabolism: serum insulin concentration.  OST T75i = oral sugar test (OST) serum insulin 
concentration at 75 minutes. OST T0i = fasting serum insulin prior to the OST. OST T75g = OST 
blood glucose concentration at 75 minutes.  IRDTi = serum insulin concentration 19 hours after 






 BCS Weight BMI Neck 
Abdominal 







Weight 0.61          
BMI 0.75* 0.88**         
Neck 0.51 0.52 0.57        
Abdominal 
girth 0.52 0.74* 0.74* 0.29       
Girth 0.82** 0.88** 0.86** 0.71* 0.53      
M:I 0.20 -0.17 -0.33 -0.40 0.05 -0.10     
OST T0i  0.49 -0.05 0.24 0.17 0.21 0.25 0.26    
OST T75i 
0.58 
(p=0.07) 0.45 0.52 0.24 
0.64 
(p=0.09) 0.55 0.31 0.79*   
OST T75g 0.14 0.17 -0.05 0.24 -0.36 0.42 0.19 0.10 0.19  




 Insulin resistance is defined as decreased responsiveness of tissues to insulin.14 Diagnosis of 
IR can be challenging due to the dynamic nature of glucose homeostasis. Glucose tolerance is often 
used as a surrogate marker of insulin resistance.  In people, multiple tests have been developed for 
evaluation of glucose tolerance and tissue insulin sensitivity in research and clinical settings, 
including IV glucose and insulin tolerance tests, oral glucose tolerance tests, and proxies.  The HEC 
is considered to be the gold standard of insulin sensitivity testing.14  The HEC prevents pancreatic 
insulin secretion in response to glucose by providing an exogenous source of insulin. In people, 
approximately 85% of infused glucose is taken up by skeletal muscle, with lesser uptake occurring in 
splanchnic bed, insulin-insensitive tissues, and adipose.15 Unfortunately, the HEC is impractical for 
widespread clinical use in human medicine due to technical challenges and expense. 
 The IVGTT was the first method used for evaluation of insulin and glucose dynamics in 
horses.72  Intravenous dynamic glucose tolerance test results are reflective of both tissue insulin 
sensitivity and pancreatic beta cell response.  In order to improve identification of tissue IR, an 
insulin-modified frequently sampled IV glucose tolerance test (FSIGTT) was subsequently 
developed.76  The minimal model analysis used to interpret the FSIGTT can characterize pancreatic 
response as well as tissue insulin sensitivity.217  Despite this improvement in diagnosis of tissue 
insulin sensitivity, the frequent sampling required makes this test challenging to use in the field.  A 
combined glucose insulin tolerance (CGIT) test was created as a more practical field test for 
evaluation of tissue insulin sensitivity following simultaneous administration of glucose and insulin.  
Less frequent sampling is performed during the CGIT compared with the FSIGTT, but the test still 
necessitates placement of an IV catheter, making it less convenient as a field test.   An oral glucose 
tolerance test (OGTT) was adapted for use in the horse85 which does not require IV catheter 
placement.  However, nasogastric intubation must be performed in order to ensure administration of 
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oral dextrose solution.  Nasogastric intubation is a procedure that horses may be stressful for some 
horses.  Stress hormones can impact glucose dynamics,218 potentially resulting in testing inaccuracy.   
 An easy, accurate test for diagnosis of equine insulin sensitivity in a clinical setting remains 
to be identified. In people, the oral glucose tolerance test is considered a reasonable surrogate 
dynamic test of insulin sensitivity in human clinical medicine, as it correlates well with the HEC.219  
In horses, the relative roles of the entero-insular axis and tissue insulin sensitivity in maintenance of 
glucose homeostasis following administration of oral glucose or intramuscular dexamethasone are 
unknown.  In this study, two recently developed field tests were compared to the HEC in order to 
determine how the new tests compared with the established method of diagnosis of insulin sensitivity.   
 The results of the current study revealed no relationship between the HEC and either the 
IRDT or OST.  A moderate correlation was observed between the IRDT and OST.  The lack of 
association between the HEC and other tests may be due to the differences in relative roles of tissue 
insulin sensitivity, pancreatic insulin secretion, and enteral absorption in each test.  The HEC 
measures tissue insulin sensitivity, isolated from the influence of pancreatic response.67  Glucose 
homeostasis following dexamethasone administrations is influenced by tissue insulin sensitivity and 
pancreatic insulin response.84,220,221   Interestingly, glucocorticoids have also been demonstrated to 
enhance enteral uptake of glucose in rats,222 but not in people.223  The OST is influenced by GI 
absorption, incretin hormones, pancreatic insulin secretion, and tissue insulin sensitivity.89,90,92 The 
absence of relationship between the HEC and other dynamic tests observed here suggests that among 
insulin sensitive horses, tissue insulin sensitivity is not the key predictor of serum insulin 
concentrations following an oral glucose challenge or administration of dexamethasone. 
 The OST was previously found to correlate well with an IVGTT in a group of 18 obese 
(BCS≥7, n=10) and non-obese (BCS≤6, n=8) horses.94  The correlation found in that study may have 
been the result of a more diverse population as 4/10 obese horses had evidence of severe IR, 
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including fasting hyperinsulinemia.94 In contrast, the horses included in the current study were 
insulin-sensitive and normoinsulinemic, although two of the selected horses had a history of an 
abnormal OST within the previous six months.  Alternatively, it may be that the IVGTT is better 
correlated to the OST as it reflects both pancreatic response and insulin sensitivity, while the HEC is 
indicative of only tissue insulin sensitivity.  In our study, there was a stronger association between the 
OST and IRDT than between the OST and HEC or IRDT and HEC.  It is attractive to speculate that 
an exaggerated pancreatic response to an IV or oral glucose challenge may be an important 
component of insulin dysregulation in the horse. 
 In addition to alterations in glucose dynamics caused by disease state, glucose homeostasis 
can also be impacted by changes in housing environment through stress of a new environment or 
changes in feed composition. Stress hormones such as catecholamines inhibit pancreatic secretion of 
insulin and impair tissue sensitivity.218  Housing changes may also influence the results of testing due 
to differences in NSC content consumed in hay compared with pasture.  Increases in dietary NSC 
content result in a rapid and dramatic increase in circulating insulin concentration,82 and long term 
feeding of a high starch diet can impair tissue insulin sensitivity.76  In this study, there was a trend 
towards a difference in T75i from OST pasture to OST stall.  However, the difference between 
insulin concentrations in both tests was small (mean, 2.7 µIU/mL) indicating that an acute change in 
housing environment has minimal influence on OST results. 
 With any oral glucose challenge test, it is likely that season will have an effect due to 
differences in NSC content. In order to further characterize differences that occurred with the OST 
across time, the OST was evaluated in 8 horses on pasture at three time points during the summer and 
fall.  In the horses of this study, there were no significant differences detected in fasting plasma 
insulin over time.  However, there was an effect of time on T75g, with horses having a higher glucose 
response in Summer than in September.  A similar, although non-significant, change in T75i was 
observed over time.  These results indicate that alterations in season can impact results of the OST.  
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In contrast, there was no seasonal impact on results of a CGIT.224  In that study, the horses were kept 
on a dry lot with free choice grass hay.  The differences between that study and the OST results 
reported here may be due to seasonal changes in pasture composition.225 
 In conclusion, this study highlights the differences between dynamic testing methodologies 
in a population of Quarter Horses of varying BCS.  Care must be taken when attempting to 
extrapolate these findings to other breeds.  Further studies are needed to identify the relative 
contribution of pancreatic secretion, tissue insulin sensitivity, and enteral glucose absorption to 
abnormalities of glucose homeostasis in the horse. 
Footnotes 
aKaro Light syrup, ACH Food Companies, Inc., Memphis, TN 
bAlphaTRAK, Abbott Laboratories, Abbott Park, IL 
cSiemens Coat-A-Count, Tarrytown, NY 












Obesity in other species is associated with oxidative stress within insulin-sensitive tissues 
and systemic circulation.  We hypothesized that obesity-associated mitochondrial dysfunction 
causes oxidative stress, which leads to skeletal muscle insulin resistance in horses.  Thirty-five 
light breed horses with body condition scores of 3/9 to 9/9 were included in the study.  
Biomarkers of oxidative stress were evaluated in skeletal muscle biopsies and plasma.  
Relationships between serum insulin concentration, body condition score (obesity) and markers 
of mitochondrial function, antioxidant capacity, and oxidative damage were evaluated.  Markers 
of oxidative stress were compared between insulin resistant (IR) and insulin sensitive (IS) horses.  
Of the markers evaluated, obesity and gene expression of mitofusin 2 (Mfn2) predicted serum 
insulin.  Regulators of mitochondrial dynamics were upregulated with obesity and IR.  While 
there was no evidence that oxidative damage was associated with IR status, lipid peroxidation and 
antioxidant capacity did increase with obesity.  Obesity is associated with increased skeletal 
muscle oxidative stress; however, upregulation of antioxidant capacity and alterations in 




Obesity is an increasingly common condition of all domestic species, including horses.   
Owner surveys and prospective observational studies in the United States and Europe indicate an 
equine obesity prevalence of 45-55%.2-4 In people, obesity is associated with the development of 
insulin resistance (IR) and type II diabetes.  Similarly, in horses, obesity is associated with IR19 and 
fasting hyperinsulinemia.20  In the obese state, fasting hyperinsulinemia may be an indication of 
pancreatic beta cell compensation for peripheral tissue insulin resistance, although it is recognized 
that hyperinsulinemia can also occur independent of IR and even induce IR.16  In people, beta cells 
are unable to maintain a sustained state of compensation and type II diabetes ensues.  In contrast, 
horses appear to be able to maintain a state of compensated insulin resistance, as type II diabetes is 
rarely recognized.226 
In people, obesity-associated insulin resistance is attributed to intracellular lipid 
accumulation,227 inflammation,158 and/or oxidative stress.147  Increased oxidative stress is a consistent 
finding in obesity, and is identified both within insulin-sensitive tissues228,229 and systemic 
circulation.229  
Oxidative stress is defined as a disruption in the balance between exposure of the cell to 
reactive oxygen species (ROS) and its antioxidant capacity resulting in a pro-oxidant state.  This pro-
oxidant state allows for structural modifications to lipids, proteins and DNA that can alter cellular 
function.  These changes may be reversible or permanent depending upon the severity and duration of 
oxidative insult to the cell.  Either increased ROS production or decreased antioxidant capacity can 
result in oxidative stress.  Increased ROS production may be due to increased production by 
mitochondria or by enzyme systems including the nicotinamide adenine dinucleotide phosphate 
oxidase and xanthine oxidase.  In people with type II diabetes, skeletal muscle has been demonstrated 
to have low mitochondrial content,110,230 decreased respiratory capacity231 and alterations in 
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mitochondrial dynamics.112,232  Impaired mitochondrial function may in part be due to decreased 
expression of transcription factors that regulate mitochondrial biogenesis and mitochondrial oxidative 
phosphorylation.122,123 
Despite the prevalence of equine obesity, mechanisms of obesity-associated insulin resistance 
remain to be identified.   Systemic oxidative stress has not been identified.140,233  However, oxidative 
stress in tissues likely precedes the development of systemic oxidative stress,229 and the role of 
oxidative stress in insulin-sensitive tissues has not been evaluated. 
We hypothesized that equine obesity is associated with mitochondrial dysfunction and 
oxidative stress, which leads to insulin resistance (Figure 14).   To test this hypothesis, relationships 
between serum insulin concentration, body condition (obesity) and markers of mitochondrial function 












Figure 14.  Schematic of the proposed relationship between obesity, mitochondrial function, oxidative 




MATERIALS AND METHODS 
Sample population 
Blood samples and skeletal muscle biopsies were collected from 35 horses.  Breeds 
represented included Quarter Horse (n=20), Thoroughbred (n=4), Paint (n=3), Paso Fino (2), 
Appaloosa (1), Missouri Foxtrotter (1), Azteca (1), Arabian (1), Tennessee Walking Horse (1), and 
Morgan (1).  Samples were collected from horses in the fall (August-October, n=5) and non-fall 
(November-July, n=30).  There were 16 mares and 19 geldings.  Age ranged from 2-27 (mean 14 +/- 
6 years).  Body condition score was assessed in all animals, while dynamic insulin sensitivity testing 
was undertaken in a subset of 19 horses, and consisted of either a frequently sampled IV glucose 
tolerance test (FSIGTT, n=6),76 hyperinsulinemic euglycemic clamp (HEC, n=3),68 or an oral sugar 
test (OST, n=10).49 Horses were considered insulin resistant (IR) on the basis of an insulin >60 
µIU/ml at 0 or 75 minutes (OST), an insulin sensitivity index <1.0 (FSIGTT), or a glucose infusion 
rate < 0.015 mmol/kg/min (HEC).  Semi-membranosus muscle biopsies were collected ante mortem 
(n=15) or immediately following euthanasia (n=20).  Samples were obtained in accordance with the 
Institutional Animal Care and Use Committee at Oklahoma State University. 
Hormone analysis 
Serum insulin concentration was measured by radioimmunoassay.a    Plasma ACTH 
concentration was determined by chemiluminescent assay.b  Both assays were previously validated 




Muscle samples were diluted in PBS and homogenates prepared using a tissue homogenizer.c  
Homogenates were centrifuged at 1000 g for 10 minutes.  Supernatant protein concentration was 
quantified using a commercially available assay.d 
Carbonylated proteins 
Carbonylated proteins were derivatized in a sample of skeletal muscle homogenate as 
previously described,235 with slight modifications.  A commercially available oxidized proteine was 
used as a positive control.  Samples were diluted in TBS and 2.5 µg of protein applied to a PVDF 
membrane via a slot blot apparatus.  The membrane was stained with Ponceau S to evaluate protein 
loading.  The membrane was then blocked in 5% milk/TBS for one hour, washed three times in 
TBS/0.05% Tween, and incubated with anti-DNPH primary antibodyf (1:13000) overnight at 4°C.  
Following washing with 5% milk/TBS/1% Tween, the membrane was incubated in secondary 
antibodyg (1:10000) at room temperature for one hour.  Detection was carried out by 
chemiluminescence.h  Bio-Rad softwared was used for quantitative analysis of the slot blot, 
accounting for any difference in protein loading with Image J software.i 
Thiobarbituric acid reactive substances 
Thiobarbituric acid reactive substances (TBARS) were evaluated in plasma and muscle 
homogenate supernatant via a commercially available kit.j   Plasma was analyzed as detailed by the 
manufacturer.  Muscle supernatants were diluted to a protein concentration of 2 mg/ml in PBS, and 
samples were analyzed according to manufacturer’s directions. 
Gene expression 
Total RNA was extracted from approximately 30 mg tissue, using TRIzol extraction.k  For 
quantitative polymerase chain reaction (PCR), total RNA was treated with DNAsel for 30 minutes at 
37°C to remove potential residual DNA, and then cDNA was transcribed according to the 
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manufacturer’s directions.m  Equine-specific primers were designed with Primer3n from published 
equine sequence datao and used to amplify peroxisome proliferator activated receptor gamma 
coactivator 1α (PGC1α), PGC1β, estrogen related receptor α (ERRα), manganese superoxide 
dismutase (MnSOD), glutathione peroxidase (GPX), glutathione synthase (GSS), glutathione redutase 
(GRS), catalase, peroxiredoxin (PRX), nuclear respiratory factor (Nrf) 1, Mfn2, and dynamin-related 
protein (Drp) 1 using β-actin as a housekeeping gene.  Quantitative PCR was performed in triplicate 
in a thermocycler.m  Reaction volume was 25 µL, consisting of 10 µL of 1/20 dilution of cDNA, 12.5 
µL of a SYBR Green master mixm and 10 mM of forward and reverse primers. 
The relative expression (RE) of each gene was calculated using the formula: 
RE =  2^ - (Ct gene of interest- Ct βactin) 
 
Mitochondrial DNA content 
DNA was extracted from approximately 15 mg of tissue using a commercially available kit.p  
Equine-specific primers were designed with Primer3n using published equine sequence datao and used 
to amplify the mitochondrial-encoded genes, nicotinamide adenine dinucleotide dehydrogenase 
(NADH-dh) and cytochrome c oxidase subunit 2 (COX2) using β-actin as a nuclear reference gene.  
Antioxidant assays 
Total SOD (TotSOD) activity was measured in muscle homogenate supernatants using a 
commercially available kitq and MnSOD activity was determined by inhibition of Cu,Zn-SOD with 
2.8 mmol sodium cyanide.  For assessment of total glutathione, 50 µL of supernatant was added to a 
reaction mixture containing 0.32 mM 5,5’-dithiobis (2-nitrobenzoic acid), 0.32 mM NADPH, 1.3 
U/ml glutathione reductase as previously described.236  Glutathione peroxidase activity was assessed 
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in 10 µL supernatant as previously described,236 using serial dilutions of bovine glutathione 
peroxidasee as an assay standard.  
Statistical analysis 
Forward stepwise regression was performed to determine the impact of BCS, age, breed, 
gender, plasma ACTH concentration and markers of oxidative stress on serum insulin concentration.  
Hormone concentrations and markers of oxidative stress were log10 transformed prior to analysis to 
improve variance for the model.  Markers of oxidative stress consisted of markers of oxidative 
damage (carbonylated proteins, skeletal muscle TBARS, plasma TBARS), markers of antioxidant 
capacity (GSH concentration, MnSOD and TotSOD activity, and gene expression of antioxidant 
enzymes), and markers of mitochondrial function (mitochondrial density and gene expression of 
PGC1α, PGC1β, ERRα, Drp1, Mfn2, Nrf1).  As both markers of mitochondrial density were strongly 
correlated (r=0.84, p<0.001), only COX2 was used in statistical analysis.  Because dynamic insulin 
sensitivity testing allows for better evaluation of tissue insulin sensitivity than fasting insulin 
concentrations, additional analysis was performed comparing markers of oxidative stress between IR 
(n=11) and insulin sensitive (IS, n=8) horses using a Mann-Whitney U test. 
In order to determine if obesity was associated with mitochondrial dysfunction or oxidative 
stress, Spearman coefficient of correlation was used to evaluate the relationship between obesity, 
mitochondrial function, and markers of oxidative stress.  As obesity may not have a substantial 
impact on oxidative stress until a state of obesity (BCS ≥7) develops, a Spearman’s rank correlation 
coefficient was also calculated using data only from horses with a BCS > 7/9.  
Because large numbers of samples had GPX activity below detection, GPX activity was 
dichotomized (detectable versus undetectable) and the frequency of detectable enzymatic activity in 




Body condition score ranged from 3/9 to 9/9 (median, 5.5).  Thirteen horses were considered 
to be obese (BCS ≥7).  Serum insulin concentrations ranged from <3.5 µIU/ml to 405 µIU/mL 
(median = 8.3 µIU/mL).  Eight horses tested IR on the basis of dynamic IR testing, and all of these 
horses were hyperinsulinemic (serum insulin concentrations >70 µIU/mL).  Plasma ACTH 
concentrations ranged from 12-166 pg/mL (median, 35.4 pg/mL).  ACTH was included in the forward 
stepwise regression model but was not retained, indicating limited influence of ACTH on serum 
insulin concentration. 
The final linear regression model contained two independent variables that accounted for 
approximately 67% (adjusted r2=0.67) of the variance in serum insulin concentration. Body condition 
score was the strongest predictor, accounting for 59% of the variance in the model (p<0.001) while 
expression of Mfn2, the regulator of mitochondrial fusion, accounted for 8% of the variance 
(p=0.012; Figure 15).  When comparing markers of oxidative stress between IR and IS horses, gene 
expression of regulators of mitochondrial dynamics (Drp-1, mitochondrial fission, p=0.007; Mfn-2, 
p=0.004), and the transcriptional regulator of oxidative phosphorylation genes, Nrf1 (p=0.006) were 
significantly increased in IR horses (Figure 16).  Antioxidant capacity was also altered with IR, with 
an increase in GSH (p=0.05) and a decrease in GSS expression (p=0.01; Table 3).  No evidence of 
skeletal muscle (p>0.05) or systemic oxidative damage was associated with IR status (Figure 17). 
When examining the relationship between BCS and markers of oxidative damage, 
carbonylated protein concentration (r=-0.48, p =0.005) was negatively correlated with BCS while 
skeletal muscle TBARS concentration was positively correlated (r=0.39, p=0.02; Figure 18).  Neither 
of these markers of oxidative damage remained significantly associated with obesity when only obese 
horses were examined.  Of the markers of antioxidant capacity, only TotSOD activity (r=0.51, 
p=0.002) was correlated with BCS, while among obese horses, both TotSOD (r=0.63, p=0.02) and 
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GSH (r=0.58, p=0.04) were correlated with increasing obesity (Table 4). There was no significant 
difference in detection of GPX activity between obese and non-obese horses (p=0.64). 
Upregulation of gene expression of Drp1 (r=0.45, p=0.007), a regulator of mitochondrial 
fission but not Mfn2 (r=0.23, p=0.11), a regulator of mitochondrial fusion was found with increasing 
BCS.  Among obese horses both Drp1 (r=0.61, p=0.03) and Mfn2 (r=0.64, p=0.02) were correlated 
with increasing obesity.  Transcriptional activators of mitochondrial biogenesis were upregulated with 
increasing BCS (ERRα, r=0.50, p=0.002; PGC1α, r=0.40, p=0.02), but there was no relationship 
between BCS and mitochondrial content or between gene expression of regulators of mitochondrial 
biogenesis and mitochondrial content (Table 4).  
Evaluation of the relationship between markers of oxidative damage, antioxidant capacity, 
and mitochondrial function, revealed that Drp1 and Mfn2 were strongly correlated with each other 
(r=0.83, p<0.001) and also correlated with other mitochondrial and antioxidant genes (Table 4).  
Mitofusin 2, Drp1, the antioxidant enzyme MnSOD, and the regulator of transcription of oxidative 
phosphorylation genes, Nrf1, were all negatively correlated with the marker of systemic lipid 
peroxidation, TBARS, while Mfn2 was positively correlated with skeletal muscle TBARS.  





































Figure 15. Final linear regression model of serum insulin concentration.  Scatterplot of relationship 
between a) BCS and serum insulin concentrations (r=0.71, p<0.001) and b) skeletal muscle Mfn-2 
expression and serum insulin concentration (r=0.43, p=0.01).  Final regression equation for prediction 




























































Figure 16.  Scatterplot of gene expression of mitochondrial dynamics and mitochondrial function 
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Figure 17.  Scatterplot of markers of oxidative damage and antioxidant capacity in skeletal muscle 
between IR and IS horses.  Line indicates median, *p≤0.05. a) skeletal muscle TBARS, b) 












































































































Figure 18.  Scatterplot of relationship between BCS and skeletal muscle and selected markers of 
skeletal muscle oxidative stress.  BCS and skeletal muscle a)TBARS (r=0.43, p=0.01), b) 
carbonylated proteins (r=-0.50, p=0.004), c) TotSOD activity (r=0.52, p=0.002), d) MnSOD activity 





Table 3.   Mitochondrial DNA content and gene expression of markers of oxidative stress in insulin 
resistant (IR) and insulin sensitive (IS) horses.  Data reported as relative expression (RE), median 
(interquartile range).   
Gene expression (RE) or 
DNA copy number 
IR (n=11) IS (n=8) P-value 
PGC1α (RE) 




PGC1β (RE) 0.030 (0.0017-0.0056) 0.0047 (0.0036-0.0097) 0.43 
ERRα (RE) 0.022 (0.0088-0.028)  0.028 (0.013-0.046) 0.39 
COX2 (DNA copy 
number) 
693 (577-1178) 1067 (678-1232) 
 
0.54 
GSS (RE) 0.0025 (0.0017- 0.0041) 0.0060 (0.0045-0.0099) 0.01 
GRS (RE) 0.00070 (0.00035-0.0019) 0.0022 (0.0011-0.0033) 0.06 
GPX (RE) 0.070 (0.044-0.12) 0.11 (0.07-0.18) 0.20 
MnSOD (RE) 0.71 (0.49-0.89) 0.89 (0.56-1.14) 0.30 
Catalase (RE) 0.0044 (0.0020-0.0075) 0.0066 (0.00090-0.018) 0.71 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Obesity-associated insulin resistance is a risk factor for the development of cardiovascular 
disease in people and laminitis in horses. In other species, obesity has been associated with 
mitochondrial dysfunction, oxidative stress and insulin resistance.109,137,229,237 In obese states, an 
increase in ROS production may initially be compensated for by an upregulation in antioxidant 
capacity.127-129  Oxidative damage occurs due to insufficient antioxidant response and eventual 
depletion of antioxidant capacity.  Normally, a majority of cellular ROS are produced by the 
mitochondrial electron transport chain, primarily complex I (NADH-dehydrogenase) and complex III 
(cytochrome bc), as a byproduct of oxidative phosphorylation.238  Excessive substrate delivery to the 
mitochondria or impaired mitochondrial function can substantially increase ROS production. 
Increased mitochondrial ROS production may affect the mitochondria in multiple ways.  ROS 
can cause mtDNA mutations due to proximity of ROS production.  ROS also stimulate mitochondrial 
biogenesis,239 although this adaptation does not appear to persist in states of chronic ROS exposure.  
Mitochondrial ROS production is also associated with alterations in mitochondrial dynamics, 
including increased fission115 and decreased fusion. Initially, increased ROS production may be 
neutralized by an upregulation in antioxidant defenses.  Within the mitochondria, the primary 
antioxidant enzymes include MnSOD, PRX, and GPX. Cytosolic free radicals may be scavenged by 
additional antioxidants, including the glutathione system and the antioxidant enzymes Cu, Zn-SOD 
and catalase.  Insufficient upregulation of antioxidants can result in a cellular pro-oxidant state and 
oxidative damage.129 
In addition to causing oxidative damage to the cell, ROS can also activate several stress 
kinases, including inhibitor of nuclear factor B kinase-β (IKKβ) and c-Jun-N-terminal kinase (JNK).  
In insulin-sensitive tissues, including skeletal muscle, both IKK and JNK can cause inhibitory (serine) 
phosphorylation of the insulin substrate protein 1, decreasing downstream signaling.  The end result is 
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decreased translocation of the glucose transporter 4 protein to the cellular membrane and decreased 
insulin-dependent glucose transport into the cell.  Fasting hyperinsulinemia is often considered a 
surrogate marker of IR in obesity, as high serum insulin concentrations are considered an appropriate 
compensatory response of pancreatic beta cells to IR.  However, because IR may precede the 
development of hyperinsulinemia, dynamic testing is an important component of evaluating tissue 
insulin sensitivity.  In people, the HEC is considered the gold standard for evaluation of insulin 
sensitivity.67  The HEC has been demonstrated to correlate well with oral glucose tolerance testing,219 
and both tests are widely used.  In contrast to people, where methodology is well-established, 
dynamic insulin sensitivity testing in horses is an evolving process with several new tests being 
developed over the past several years.  Over the course of sample collection for the present study, 
recommendations for testing insulin sensitivity varied.  In addition, it was not feasible to do the more 
resource intensive tests in all animals.  Therefore, dynamic testing was performed in a subset of 19 
horses using a variety of methods.  Additionally, fasting serum insulin concentrations were used as an 
index of insulin sensitivity across the entire population. 
In people, skeletal muscle IR has been attributed to impaired mitochondrial function.  Obesity 
is associated with decreased oxidative phosphorylation within skeletal muscle, which leads to 
increased mitochondrial ROS production, oxidative stress, and impaired insulin signaling.240 Impaired 
insulin-dependent glucose transport has been identified in the skeletal muscle of IR horses, but the 
mechanism causing the defect has not been elucidated.105  Therefore, in this study, we chose to 
evaluate several markers of mitochondrial function, including mitochondrial biogenesis, content, and 
dynamics to determine if mitochondrial function was impaired in horses with obesity-associated IR.  
Because impaired mitochondrial function is associated with increased ROS production, measurements 
of oxidative damage and antioxidant capacity were undertaken.  
Mitochondrial dynamics describes the morphological changes mitochondria can undergo in 
response to cellular environment and intracellular signals.  The mitofusins, Mfn1 and Mfn2, are 
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membrane proteins involved in mitochondrial fusion.  Fusion is the process of mitochondrial union, 
which allows for transfer of mtDNA and rescue of membrane potential.  Mitochondria may also 
fragment in order to allow for removal of dysfunctional parts of the mitochondria, a process known as 
fission.  Fission is mediated primarily by two proteins, Drp1 and fission 1 (Fis1). Excessive fission or 
inadequate fusion causes the formation of small, globoid mitochondria, while the converse results in 
formation of long reticulated networks.  The maintenance of a normal mitochondrial network is 
important for mitochondrial function, and downregulation of Mfn2113 or Fis1114 results in impaired 
oxidative phosphorylation.  In the horses of this study, the only oxidative stress marker that was 
predictive of plasma insulin concentration was expression of Mfn2. Mfn2 and Drp1 expression were 
also increased in IR horses and with increasing obesity among obese horses.   
In addition to its key role in mitochondrial morphology, Mfn2 functions as a regulator of 
metabolism. Mitofusin 2 has been demonstrated to be important in mediating glucose oxidation, 
insulin signaling, and mitochondrial oxidative phosphorylation in skeletal muscle and liver, and 
overexpression of Mfn2 improves glucose oxidation and mitochondrial oxidative phosphorylation.117   
Gene expression of Mfn2 in skeletal muscle is decreased in human obesity113 and type II 
diabetes.116  An increase in mitochondrial-associated fission protein, Fis-1, and mitochondrial 
fragmentation have been observed in high fat fed and genetically obese rodents.112  Taken together, 
these findings indicate a shift in mitochondrial dynamics towards fission in the obese, IR state.  In 
contrast, in this study, regulators of both fission and fusion were increased with IR, while only the 
regulator of fusion, Mfn2, was predictive of serum insulin concentrations.  This suggests that Mfn2 
may be upregulated as a protective mechanism, either in response to a defect in glucose metabolism 
or in response to increased fission. In a normal physiological state, mitochondrial dynamics are auto-
regulated and increased fission activates signaling mechanisms that lead to increased fusion.  
Increased ROS production is associated with increased mitochondrial fission in cultured myoblasts 
during conditions of excessive glucose115 or saturated fatty acids,112 and inhibition of fission 
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normalizes ROS level.241 Activation of Mfn2 is protective against ROS-induced damage to the 
mitochondrial matrix.111 
Mitochondrial dynamics proteins also play an important role in mitochondrial biogenesis.  
Mitochondrial biogenesis is the process of mitochondrial division, which is a complex process that 
involves replication of mitochondrial DNA (mtDNA) and incorporation of proteins and lipids into the 
mitochondrial membrane.118  The peroxisome proliferator-activated receptor gamma coactivators are 
considered to be the master regulators of mitochondrial biogenesis.  PGC1β is constitutively active, 
and appears to be the most important regulator under normal physiologic conditions, while PGC1α is 
inducible. Estrogen related receptor α (ERRα) is a transcriptional factor that is downstream of 
PGC1α and PGC1β.  ERRα activates transcription of regulators of oxidative phosphorylation genes, 
including Nrf1. Mitochondrial biogenesis may be assessed by gene expression or protein content of 
regulators of mitochondrial biogenesis, or through evaluation of mitochondrial content.  
Mitochondrial content may be evaluated by electron microscopy or indirectly, through measurement 
of mitochondrial DNA content.242  Each mitochondria has between 2-10 genome copies.243  
Therefore, comparison of mitochondrial DNA copy number to nuclear DNA copy number can 
generate an approximation of mitochondrial content. 
In this study, Nrf1 was increased with IR, but not correlated with increasing BCS.  
Interestingly, mitochondrial biogenesis was upregulated with obesity, as demonstrated by increased 
transcription of PGC1α and ERRα.  This upregulation in transcriptional activators of biogenesis in 
BCS was not paralleled by an increase in Nrf1 transcription or mitochondrial copy number.  In 
contrast, in people with type II diabetes, there is a coordinated reduction of genes involved in 
mitochondrial biogenesis, including decreased mitochondrial PGC1α, PGC1β, ERRα, and Nrf-1122,123 
and decreased mitochondrial content.109,110  The findings reported here may indicate impaired 
signaling between ERRα and transcription of oxidative phosphorylation genes that occurs with 
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obesity.  Although PGC1α and PGC1β are considered the master regulators of biogenesis, a 
functional ERRα is critical for downstream signaling.121  The absence of response of mitochondrial 
DNA replication in light of the upregulation of regulators of biogenesis with increasing BCS warrants 
additional investigation.  In the IR state, the increased expression of Nrf1, a regulator of oxidative 
phosphorylation gene transcription, may be a physiological response to increased substrate demand 
by enhancing cellular respiratory function.  
Lipid peroxidation increased while protein oxidation decreased with increasing BCS, 
although this relationship was not maintained when examining obese horses only.  The discordant 
findings between TBARS (increased) and protein carbonyls (decreased) across BCS may be reflective 
of upregulated proteasomal-mediated degradation of oxidized proteins.244  Increased TBARS 
concentration may be a function of increased intramyocellular lipid content and increased availability 
of lipid for peroxidation by intracellular ROS.127,181 The increase in antioxidant capacity paralleling 
obesity suggests compensation for an increase in cellular ROS exposure occurring with BCS.   
In conclusion, although several lines of evidence support the hypothesis that increased ROS 
is associated with equine obesity and obesity was a strong predictor of IR, there was no relationship 
between markers of oxidative stress and IR.  It is of interest that Mfn2, a regulator of mitochondrial 
fusion, a process that protects the mitochondrial against ROS damage, was upregulated in horses with 
IR, suggesting alterations in mitochondrial dynamics may be protective against increased ROS 
associated with obesity.  Further studies are needed to confirm the role of mitochondrial dynamics in 
obesity and IR in horse. 
Footnotes 
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Local (skeletal muscle and adipose) and systemic inflammation are implicated in the 
development of obesity-associated insulin resistance (IR) in people.  In horses, obesity is not 
strongly or consistently associated with systemic inflammation.  The role of skeletal muscle 
inflammation in the development of equine obesity-associated IR remains to be determined.  We 
hypothesized that skeletal muscle inflammation causes obesity-associated IR in horses.  Thirty-
five light breed horses with body condition scores of 3/9 to 9/9 were included in the study.  
Inflammatory biomarkers were evaluated in skeletal muscle biopsies and plasma.  Relationships 
among local and systemic inflammatory markers, obesity, and serum insulin concentration were 
evaluated.   Inflammatory biomarkers were compared between insulin resistant (IR) and insulin 
sensitive (IS) horses. None of the inflammatory biomarkers increased with serum insulin 
concentration.  In contrast, skeletal muscle TNFα and plasma serum amyloid A concentrations 
were negatively correlated with obesity and lower in IR compared to IS horses.  We conclude that 
skeletal muscle inflammation is not a primary mechanism for development of equine obesity-




Obesity in people is associated with a low-grade, chronic inflammatory state.245 Obesity is 
primarily due to accumulation of white adipose tissue (WAT).  Historically, WAT was recognized for 
its role as a primary site of energy storage.  More recently, it has been identified as an important 
endocrine organ that secretes proteins, known as adipokines, which are involved in regulation of 
metabolism, coagulation, and inflammation.  Key inflammatory adipokines secreted by WAT include 
the cytokines IL-6 and tumor necrosis factor α (TNFα) and the acute phase reactants, serum amyloid 
A (SAA) and c-reactive protein (CRP).153,246-248    
High concentrations of circulating inflammatory cytokines have been implicated in the 
development of type II diabetes.152  Circulating inflammatory cytokines, primarily TNFα, perpetuate 
the inflammatory state by activating the intracellular stress kinases, inhibitor of nuclear factor kappa 
B (NFκB) kinase β (IKKβ), Jun N terminal kinase (JNK) and mitogen activated protein kinase 4.102  
IKKβ causes translocation of NFκB, allowing for transcription of inflammatory cytokines and 
perpetuation of the pro-inflammatory state.  In insulin-sensitive tissues, including skeletal muscle, 
JNK interacts directly with the insulin signaling pathway by causing inhibitory phosphorylation of the 
insulin receptor substrate 1 protein. A pro-inflammatory state has been identified within skeletal 
muscle of people with type II diabetes.249,250  Thus, it has been proposed that inflammation within 
skeletal muscle may in part be responsible for obesity-associated insulin resistance. 
  In contrast to studies in people and in mice, research into obesity in horses has not 
demonstrated a consistent association between systemic inflammation and obesity. Initial studies 
found that obesity in horses was correlated with systemic inflammation,19,166 but these findings were 
confounded by failure to control for age in the obese population surveyed. In contrast, in ponies with 
a history of laminitis, circulating TNF-α concentrations were not correlated with obesity or IR, but 
did correlate with age.139 Age has been independently associated with a pro-inflammatory state in 
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horses.167  In Thoroughbred geldings fed to promote weight gain, there was no correlation between 
BCS and serum TNFα.168 
The role of systemic inflammation in equine obesity-associated insulin resistance is similarly 
unclear.  Circulating pro-inflammatory cytokine concentrations do not appear to be a key component 
of obesity associated IR.  A previous study of hyperinsulinemic obese horses demonstrated a trend 
toward decreased circulating TNFα and decreased mononuclear inflammatory cytokine expression 
when compared with lean controls.140 IL1β, IL6, and TNFα plasma concentrations were not 
correlated with obesity or plasma insulin concentrations in another study.169 There have been 
conflicting findings with respect to the acute phase response. No change in CRP concentrations was 
found in hyperinsulinemic obese horses compared to controls.140  In contrast, SAA did correlate with 
insulin concentrations and weakly with BCS.169 
Despite multiple investigations into the relationship between systemic inflammation, obesity 
and insulin resistance in horses, knowledge of tissue inflammation is limited.  Inflammatory cytokine 
gene expression in adipose tissue of IR horses was not significantly different than that of IS 
controls.77  Furthermore, TNFα protein content was increased in visceral adipose but not skeletal 
muscle or subcutaneous adipose of IR horses compared to IS controls.170  Notably, in both of these 
studies, horses were stratified solely on the basis of dynamic insulin sensitivity testing and were 
similar with respect to BCS. 
We hypothesized that obesity-associated skeletal muscle inflammation leads to the 
development of IR in horses.  To test this hypothesis, relationships between serum insulin 
concentration, obesity (BCS), and markers of local and systemic inflammation were explored. 




Blood samples and skeletal muscle biopsies were collected from 35 horses.  Breeds 
represented included Quarter Horse (n=20), Thoroughbred (n=4), Paint (n=3), Paso Fino (2), 
Appaloosa (1), Missouri Foxtrotter (1), Azteca (1), Arabian (1), Tennessee Walking Horse (1), 
Morgan (1).  There were 16 mares and 19 geldings.  Age ranged from 2-27 (mean 14 ± 6 years).  
Body condition score (BCS) was assessed in all animals, while dynamic insulin sensitivity testing was 
undertaken in a subset of 19 horses, and consisted of either a frequently sampled IV glucose tolerance 
test (FSIGTT, n=6),76 hyperinsulinemic euglycemic clamp (HEC, n=3),68 or an oral sugar test (OST, 
n=10).49 Horses were considered insulin resistant (IR) on the basis of an insulin >60 µIU/ml at 0 or 75 
minutes (OST), an insulin sensitivity index <1.0 (FSIGTT), and a glucose infusion rate < 0.015 
mmol/kg/min (HEC).  Semi-membranosus muscle biopsies were collected ante mortem (n=15) or 
immediately following euthanasia (n=20).  Samples were obtained in accordance with the 
Institutional Animal Care and Use Committee at Oklahoma State University. 
Hormone analysis 
Serum insulina and plasma α-melanocyte stimulating hormoneb (α-MSH) concentrations 
were measured by radioimmunoassay. Assays were previously validated for use in horses.203,251  
Muscle TNFα 
Muscle samples were diluted in PBS and homogenates prepared using a tissue homogenizer.c  
Homogenates were centrifuged at 1000 g for 10 minutes.  Supernatant protein concentration was 
quantified using a commercially available assay.d  Skeletal muscle TNFα was evaluated by ELISA.e  
Sample dilutional parallelism was assessed in a spiked sample with high TNFα concentrations 
(r2=0.95, p=0.005).  Percent recovery was determined by spiking a pooled low homogenate sample 
with reconstituted standard, at concentrations ranging from 62.5-1000 pg/mL.  Recovery (mean ± 




Total RNA was extracted from approximately 30 mg skeletal muscle using TRIzol 
extraction.f   For quantitative polymerase chain reaction (PCR), total RNA was treated with DNAseg 
for 30 minutes at 37°C to remove potential residual DNA, and then cDNA was transcribed according 
to the manufacturer’s directions.h  Equine-specific primers were designed with Primer3i using 
published equine sequence dataj and used to amplify TNFα, IL1 and IL6 mRNA using β-actin and 
GAPDH as housekeeping genes. β-actin and GAPDH were determined to have the best stability as 
housekeeping genes following analysis with a commercially available software program.l  
Quantitative PCR was performed in triplicate in a thermocycler.h  Reaction volume was 25 µL, 
consisting of 10 µL of 1/20 dilution of cDNA, 12.5 µL of a SYBR Green master mixh and 10 mM of 
forward and reverse primers. 
The geometric mean of both housekeeping genes was used to create a normalization factor.  
This normalization factor was applied to each gene to determine relative expression (RE). 
Systemic inflammatory biomarkers 
Serum amyloid Am and TNF-αe were measured in plasma using commercially available 
ELISAs as previously described.19,252 
Statistical analysis 
Forward stepwise regression was performed to determine the impact of BCS, age, breed, 
gender, and markers of inflammation on serum insulin concentration.   For the purpose of statistical 
analysis, breed was dichotomized into Quarter Horses (n=20) and other breeds (n=15).  Hormone 
concentrations and inflammatory biomarkers were log10 transformed for the model.  Because dynamic 
insulin sensitivity testing allows for better evaluation of tissue insulin sensitivity than fasting insulin 
concentrations, skeletal muscle and systemic markers of inflammation in IR (n=8) horses was 
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compared to that of IS (n=11) horses using a Mann-Whitney U test.  Since the ratio of pro and anti-
inflammatory cytokines is often considered a better indicator of inflammatory status than either 
cytokine alone, a ratio of TNFα:IL10 and IL6:IL10 gene expression was also evaluated in IR and IS 
horses. 
 In order to determine the role of obesity in the development of local and systemic 
inflammation, a Spearman rank correlation coefficient was calculated to evaluate the relationship of 
BCS and skeletal muscle and circulating inflammatory biomarkers.  
RESULTS 
Body condition score ranged from 3/9 to 9/9 (median, 5.5).  Thirteen horses were considered 
to be obese (BCS ≥7).  Serum insulin concentrations ranged from <3.5 µIU/ml to 405 µIU/mL 
(median, 8.3 µIU/mL).  Eight of 19 horses were IR on the basis of dynamic testing.  All of these 
horses were also hyperinsulinemic with serum insulin concentrations >70 µIU/mL. Plasma samples 
from IR horses were collected during the summer (June-July, n=7) and spring (March-May, n=1).  
Plasma samples from IS horses were collected during fall (Aug-Nov, n=1), winter (Dec-Feb, n=2), 
and spring (Mar-May, n=8).  Plasma α-MSH concentrations ranged from 7.5-345 pg/ml (median, 
42.5). 
The final regression model for prediction of serum insulin concentration consisted of BCS, 
gender, and age (adjusted r2=0.72, p<0.001; Table 5).  Body condition score accounted for 42% of the 
variance of the serum insulin concentrations (p<0.001), while age accounted for 23% (p=0.001) and 
gender for 9% (p=0.02).  When comparing skeletal muscle inflammatory biomarkers of IR to IS 
horses, TNFα protein content was decreased in IR horses (Figure 19).  No significant differences in 
TNFα, IL6, IL10, TNFα:IL10, or IL6:IL10 gene expression were detected between groups (Figure 
19). Simple correlation analysis between BCS and skeletal muscle inflammatory biomarkers revealed 
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a moderate negative association between obesity and skeletal muscle TNFα (r=-0.40, p=0.04), but no 
association with IL6 or IL10 gene expression (Table 6).  There was a trend towards a relationship 
between skeletal muscle and plasma TNFα (r=0.33, p=0.06), but no other associations between 
systemic inflammation and skeletal muscle inflammation were found. 
The relationship between systemic inflammation, IR status, and obesity was also evaluated.  
Serum amyloid A (r=-0.38, p=0.05) and plasma TNFα (r=-0.40, r=0.02) were negatively correlated 
with BCS and SAA was significantly decreased in IR horses compared to IS horses (p=0.007, Figure 
20).  Plasma TNFα was not associated with IR status.  Alpha MSH was positively correlated with 















































































































































Figure 19.  Skeletal muscle inflammatory markers in IR and IS horses. a) TNFα protein content b) 
TNFα gene expression, c) IL6 gene expression, and d) IL10 gene expression, e) IL6:IL10 gene 














































































Figure 20.  Comparison between systemic markers of inflammation in IR and IS horses: a) TNFα, b) 








Table 5.  Predictors of serum insulin concentration using linear regression modeling.  Final regression 
equation: -1.251 + 0.76(BCS) + 0.433(age) -0.287(gender). 
Step Variable r2 adjusted r2 P 
1 BCS 0.44 0.42 <0.001 
2 Age 0.67	   0.64	   0.001	  
3 Gender 0.75 0.71 0.021 
 



















α-MSH 0.65**         
Plasma 
TNFα  -0.40* -0.16        
Plasma 
SAA -0.38* -0.18 0.00       
IL6 (RE) 0.11 0.06 0.23 -0.12    
  
IL10 (RE) 0.16 0.01 0.36* -0.07 0.64**   
  
TNFα  (RE) 0.23 0.06 -0.14 0.02 0.26 0.58**    
IL6:IL10 
(RE) 0.11 0.25 -0.24 -0.09 -- -- -0.05   
TNFα:IL10 
(RE) 0.06 0.22 -0.29 0.09 0.006 -- -- --  
TNFα  
muscle -0.40* -0.22 
0.33 









 Inflammation is considered to be a central component of obesity-associated insulin resistance 
in people, with systemic and local (adipose and skeletal muscle) inflammation reported.  In horses, 
the relationship between obesity and inflammation, or inflammation and insulin resistance, remains 
less clear.  To date, most equine studies have focused on systemic inflammation.  The limited 
investigations of the relationship between local inflammation and IR have used horses of similar BCS 
in an attempt to evaluate IR without the obesity confounder.77,170  However, mechanisms of IR in 
obese and non-obese states are not always similar.253  Given the prevalence of obesity-associated IR 
in horses, it is important to investigate mechanisms of IR while including the obesity-IR interaction. 
Skeletal muscle is the most important site of insulin-mediated glucose disposal in the post-
prandial state, with an estimated 67% of glucose uptake occurring within this tissue in people.11  
Whole body IR is typically reflective of IR within skeletal muscle.  In horses, IR can be challenging 
to identify.  Multiple dynamic insulin tolerance tests have been developed for use in the 
horse,68,76,78,254 but few have been compared to the HEC,255 which is considered the gold standard in 
diagnosis of human IR.  In this study, multiple dynamic tests were employed for diagnosis of IR due 
to emergence of new, and potentially improved, methods for diagnosis of IR during the sample 
collection period.  Because comparisons between dynamic tests are not standardized, and not all 
horses underwent dynamic testing, fasting serum insulin concentration was used as a surrogate 
marker for IR across the population.  All horses considered to be IR on the basis of dynamic testing 
also had fasting hyperinsulinemia.  Dynamic testing also confirmed insulin sensitivity in 11 horses 
with normal fasting insulin. 
In other species, obesity-associated inflammation is mediated by a number of cytokines.  
TNFα is a key pro-inflammatory cytokine that initiates increased transcription of pro-inflammatory 
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cytokines, and activates stress kinases that interfere with insulin signaling.  Interleukin 6 is an 
important mediator of the hepatic acute phase response that is secreted primarily from activated 
lymphocytes and macrophages.256  It is also recognized as an important adipokine and myokine 
involved in insulin signaling.257  Interleukin 10 is primarily an anti-inflammatory cytokine that 
counters the effect of IL6 and TNFα.  Interleukin 10 also appears to counter-regulate the effects of 
IL6 and TNFα on insulin signaling.  In mice, infusion of IL6 decreased skeletal muscle insulin 
signaling, an effect that was ameliorated by infusion of IL10.258  In order to better understand the role 
of skeletal muscle inflammatory state in insulin resistance, gene expression of both pro-inflammatory 
(TNFα, IL6) and anti-inflammatory (IL10) cytokines was evaluated.  Tumor necrosis factor α was 
also evaluated at the protein level, both within skeletal muscle and systemic circulation. 
In the current study, signalment factors (obesity, age, and gender) were the only significant 
predictors of serum insulin concentrations, with mares having higher insulin concentrations.  The 
findings reported here suggest that in horses, signalment is more important than inflammation in 
altering insulin sensitivity.  Insulin sensitivity has been previously demonstrated to decline with age 
in horses.19  In people, the decline in insulin sensitivity observed with age is thought to be due to a 
combination of obesity and a decline in physical activity.259  
Insulin resistance and type II diabetes are associated with increased skeletal muscle TNFα 
concentrations in people.164,165  In contrast, in our horses, skeletal muscle TNFα was negatively 
associated with obesity and IR status. Gene transcription of pro- or anti-inflammatory cytokines was 
not altered with IR status or obesity.  These findings indicate that skeletal muscle inflammation is not 
an important contributor to equine obesity-associated IR.  
In agreement with a previous study from our laboratory, the current data showed a decrease 
in systemic inflammation in IR horses compared to IS horses and with obesity.140  In contrast, in 
human obesity, both circulating acute phase proteins and TNFα are increased.153,246 Although acute 
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phase proteins are typically produced by hepatocytes, in states of obesity, adipose tissue is recognized 
as an important site of production and secretion.153,247,248  In horses, SAA appears to be a better 
indicator of acute inflammation than other acute phase proteins as SAA normally circulates at low 
concentrations but has a more rapid, profound (several hundred fold) increase in response to an 
inflammatory stimulus.252  Previously, SAA was reported to have a moderate correlation with insulin 
concentration and a weak correlation with BCS in horses.169  In contrast, no relationship between 
SAA and BCS was found in a subsequent study of laminitis prone ponies but a significant impact of 
season on SAA concentration was reported, with concentrations higher in winter than summer.260  
Seasonal differences in sample collection between IR and IS horses may be responsible for 
discrepancies between our study and previous reports; Suagee et al collected samples during June and 
July,169 while in this study, samples were collected throughout the year.  
The relationship between α-melanocyte stimulating hormone (α-MSH), IR status and obesity 
is intriguing. Alpha melanocyte stimulating hormone, a pro-opiomelanocortin peptide produce by the 
pars intermedia of the pituitary, is a potent anti-inflammatory hormone.261,262  In this study, there was 
no relationship between α-MSH and other pro- or anti-inflammatory mediators, suggesting that 
inflammation was not the main stimulus for α-MSH secretion in this population.  However, it may be 
that high circulating α-MSH represses obesity-associated inflammation.  In addition to its anti-
inflammatory effect, α-MSH is also an important regulator of satiety.263,264 The parallel increase in α-
MSH and BCS in the horses of this study suggest α-MSH may contribute to obesity in horses through 
its role in central regulation of appetite.  
In summary, despite what has been reported in other species, we were unable to show a 
relationship between skeletal muscle or systemic inflammation and obesity-associated IR.  Our 
findings indicated that obesity was the strongest predictor of insulin resistance, with no significant 
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positive influence of either systemic or local pro-inflammatory biomarkers.  The mechanism of 
equine obesity-associated IR remains to be discovered. 
Footnotes 
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Equine metabolic syndrome was a term coined in 200210 to describe a condition in horses 
characterized by obesity, regional adiposity, laminitis, and insulin resistance or 
hyperinsulinemia.45  The term equine metabolic syndrome was chosen due to similarities between 
EMS and human metabolic syndrome, which is cluster of risk factors for cardiovascular disease, 
including central obesity, fasting hyperglycemia, hypertension, and dyslipidemia.46  Equine 
metabolic syndrome has been associated with adverse health consequences including infertility in 
mares and exercise intolerance.  However, the primary health concern associated with EMS is the 
development of laminitis, a painful condition that in some cases necessitates humane euthanasia 
in affected horses. Recent data indicates that in horses presenting to a hospital for laminitis, 
endocrine disease is the most common cause of laminar disease.32  
Despite being a recognized clinical syndrome for over ten years,10 EMS remains a 
challenging disease to diagnose and treat, in large part because the mechanisms that lead to 
insulin resistance and hyperinsulinemia in horses are not understood.  Altered insulin regulation 
and glucose homeostasis may occur by disruption anywhere along the pathway of insulin-
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mediated glucose disposal, including enteral glucose absorption, pancreatic insulin secretion, hepatic 
gluconeogenesis, or insulin-mediated glucose uptake in skeletal muscle or adipose.  In people, 
skeletal muscle insulin resistance has long been believed to be a central defect in the development of 
type II diabetes.265  Therefore, we set out with the central hypothesis that insulin resistance within 
skeletal muscle was the primary defect in horses with EMS. In people, oxidative stress,266 
inflammation, 148 and lipotoxicity267 are key mechanisms associated with skeletal muscle insulin 
resistance.   
Emerging evidence at the time of initiation of the study indicated that mitochondrial dysfunction 
was a key mechanism of oxidative stress and insulin resistance within skeletal muscle of insulin 
resistant humans.240  Increased systemic oxidative stress has not been previously been identified either 
in a population of previously laminitic ponies compared to non-laminitic counterparts139 or in a 
population of hyperinsulinemic obese horses compared to lean, normoinsulinemic horses.140  
However, systemic oxidant status is not always reflective of tissue oxidant status.  We hypothesized 
that obesity-associated mitochondrial dysfunction leads to oxidative stress and insulin resistance 
within skeletal muscle of obese horses.  Because preliminary investigations into mitochondrial 
content and function failed to yield significant findings, a more global approach exploring oxidative 
stress within skeletal muscle was undertaken, including analysis of antioxidant enzyme activities, 
antioxidant concentrations, and markers of lipid peroxidation and protein oxidation within skeletal 
muscle.  Using serum insulin concentration as a surrogate marker of insulin resistance, linear 
regression modeling did not identify any marker of oxidative damage to be predictive of IR.  
However, Mfn2, a regulator of mitochondrial fusion, was predictive of IR.  Furthermore, expression 
of Mfn2 and fission (Drp1) were increased in IR horses. This evidence suggests that mitochondrial 
dynamics are altered in association with IR.  In people and rodents, mitochondrial dynamics are 
altered with obesity and type II diabetes; however, this involves an overall shift in mitochondrial 
dynamics towards fission.112,116  In contrast, in horses, there appears to be a shift toward fusion.  
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Importantly, analysis of mitochondrial dynamics was confined to gene expression analysis.  Further 
investigation into the role of mitochondrial dynamics in EMS is warranted, including measurement of 
fission and fusion protein content and direct evaluation of changes in morphology using fluorescent 
labeling techniques.268 
As mitochondrial dysfunction and oxidative stress did not appear to be key mechanisms of equine 
skeletal muscle insulin resistance, a second hypothesis was constructed.  Due to the strong association 
between obesity, IR, and local157,158,164,165 and systemic149,151 inflammation in people, we hypothesized 
that inflammation within skeletal muscle of horses causes equine insulin resistance. Gene expression 
of pro- or anti-inflammatory cytokines within skeletal muscle and TNFα protein content of skeletal 
muscle revealed no significant differences between IR and IS horses.  As both skeletal muscle164 and 
adipose tissue157,158 can secrete inflammatory cytokines in states of obesity, systemic inflammation 
was also assessed.  There was no evidence of a positive association between systemic or skeletal 
muscle inflammation and obesity, IR, or hyperinsulinemia in the horses of this study.  The findings 
relating to skeletal muscle inflammation should be interpreted with caution for several reasons.   First, 
only one protein (TNFα) was evaluated.  TNFα was chosen as previous studies have documented an 
increase in skeletal muscle of people with type II diabetes.164,165  However, in this study, TNFα was 
negatively associated with IR and obesity.  It may be that other pro- or anti- inflammatory cytokines 
are more important in characterizing the inflammatory state of equine obesity and IR.  There were no 
significant differences in pro- or anti- inflammatory gene expression between IR and IS horses, but 
cytokine gene expression may not always be reflective of protein content due to post-transcriptional 
regulation.269  However, when coupled with analysis of systemic inflammatory markers in this and 
other19,140,166,270 studies, it appears unlikely that inflammation is the principle mechanism of equine IR.   
When evaluating the results found here, it is important to take into account that the horses of 
the obese, IR group did not all have EMS, as defined by the 2010 ACVIM consensus statement.45  In 
that statement, laminitis was defined as a necessary characteristic for inclusion as an EMS-affected 
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horse.  In this study, only 4/8 IR, hyperinsulinemic horses had a history of clinical laminitis.  Obesity-
associated IR may have a different mechanism in horses suffering from laminitis than in horses that 
are not affected by laminitis.  Alternatively, laminitis may merely be an indication of chronicity or 
severity of obesity-associated IR and hyperinsulinemia.  Regardless, it is important to recognize that 
findings in obese, hyperinsulinemic non-laminitic equids may not be applicable to those with 
laminitis. 
The wide variation in signalment represented in this study should also be considered when 
drawing conclusions.  Ten breeds were represented, with age of included horses ranging from 2-27 
years. In linear regression modeling, breed was not retained for prediction of serum insulin when 
evaluating either inflammation or oxidative stress.  However, for the purposes of the model, breed 
was dichotomized into Quarter Horse and other breed.  The other breeds represented included both 
historically EMS-predisposed as well as EMS-resistant breeds.  The diversity of breeds included 
coupled with the large proportion of Quarter Horse-type breeds represented in the population limit 
our ability to interpret the influence of breed on our findings.  It may be that some breeds which were 
not well-represented in this study (i.e., breeds other than the Quarter Horse) have a primary defect in 
skeletal muscle insulin signaling that this study was could not identify.  Differences in lipid profiles, 
insulin sensitivity and glucose tolerance have been previously been demonstrated between 
breeds.68,70,79,271  Although findings from early studies were limited by a small number of 
animals68,70,79 and a failure to control for obesity,68,70 anecdotal reports of increased incidence of EMS 
in certain breeds10,45,49 supports the idea that alterations in metabolism may precede the development 
of both obesity and IR in some breeds.  However, a recent study did not demonstrate differences in 
fasting insulin concentrations or lipid profiles between an EMS-predisposed breed (Morgan horses) 
and an apparently EMS-resistant breed (Thoroughbred horses).272  Furthermore, in a recent 
epidemiological study of hyperinsulinemia, obesity and age but not breed were associated with an 
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increased risk of hyperinsulinemia.20  The relationship of breed with development of EMS deserves 
further study. 
Signalment factors other than breed may also be important in assessment of IR and EMS.  
Age has been demonstrated to be negatively associated with insulin sensitivity in a population of 
mares.19  Both age and gender (female > male) were associated with serum insulin concentration in 
the evaluation of inflammation in the present study.  However, there was no significant difference in 
age or gender between IR and IS horses.  Future studies evaluating mechanisms of equine insulin 
dysregulation or EMS should include a larger population of horses in order to allow for impact of 
signalment factors, including breed, to be adequately assessed. 
In people, obesity and type II diabetes are typically considered to be chronic disease states.  
In the horses of the current study, records on subjective or objective assessments of obesity were not 
available.  Therefore, the relationship between duration of excessive adiposity and development of 
skeletal muscle oxidative stress or inflammation cannot be accurately assessed.  However, several 
horses were members of a research herd and had been identified as “easy keepers” for several years, 
with a propensity towards obesity.  Other horses were very obese with markedly elevated fasting 
serum insulin concentrations, perhaps suggesting chronicity within the IR population studied.  
Differences in duration of obesity may have impacted findings. In a mouse model of dietary-induced 
obesity, adipose inflammatory cytokine expression varied across time.159  In mice with either diet or 
genetically-induced obesity, markers of oxidative stress can vary over time.127,229 Therefore, is 
possible that inflammation or increased ROS production is an early event in the pathogenesis of 
equine obesity-associated IR that is not detected at later stages. 
As two key mechanisms of skeletal muscle insulin resistance did not appear to be associated 
with equine IR or hyperinsulinemia, the possibility of an alternative primary site of insulin 
dysregulation was explored by use of dynamic insulin sensitivity testing.  Multiple tests have been 
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recently developed49,78,94 or modified80 for diagnosis of IR in the field, but none have been compared 
to the gold standard of tissue insulin sensitivity, the hyperinsulinemic euglycemic clamp (HEC).  In 
this experiment, the HEC was compared to an insulin-response to dexamethasone test (IRDT) and the 
recently developed oral sugar test (OST).49,94 Eight horses were chosen for this study.  In an attempt 
to look at the relationship between tests across a broad spectrum of insulin sensitivity, three obese 
horses were included, two of which were previously documented to be IR based on results of an OST.  
At the time of the experiment, all horses had a normal response to an oral glucose challenge based on 
previously recommended cut-off values,49 although there was a reasonable range of glucose 
metabolism indices and glucose metabolism to serum insulin concentration ratios.  Unfortunately, the 
true status of tissue insulin sensitivity in this group of horses is not known, as breed-specific reference 
ranges for the HEC have not yet been established.  Despite these limitations, the absence of 
correlation between the HEC and the OST or IRDT, suggests that in horses, tissue insulin sensitivity 
is not the primary determinant of glucose and insulin disposition following an oral glucose challenge.  
Furthermore, the absence of correlation between the HEC and fasting serum insulin concentrations 
suggest that tissue insulin resistance may not be the primary mechanism driving fasting serum insulin 
concentrations.  All of the horses of this study were Quarter Horses, so findings may not apply to 
other breeds. 
Interestingly, while our obese horses appeared to be insulin sensitive, previous studies have 
indicated a state of insulin resistance among non-obese, normoinsulinemic, apparently healthy horses 
using dynamic test results.77,105,170,273  Unfortunately, dynamic testing may be inherently stressful to a 
horse due to the use of restraint within a stall, catheter placement, and frequent sampling required.   
Stress hormones are known to promote a state of insulin resistance in people.218  Therefore, it may be 
that some thin horses are inappropriately diagnosed as IR on the basis of dynamic testing under 
stressful conditions or that some dynamic tests are not useful for the diagnosis of insulin 
dysregulation in horses.  
101	  
Taken together, the results from these experiments on mechanisms of impaired insulin 
signaling within skeletal muscle and dynamic insulin sensitivity and glucose tolerance testing suggest 
that in horses, skeletal muscle insulin resistance may not be the central mechanism of insulin 
dysregulation.  Instead, hyperinsulinemia may precede the development of tissue insulin resistance. 
Hyperinsulinemia is closely linked to the presence of insulin resistance, and hyperinsulinemia may 
induce IR.16,274  Interestingly, recently it has been suggested that hyperinsulinemia may be the initial 
defect in glucose homeostasis and insulin disposal in people.16,275   
As the mechanism of insulin dysregulation in the horse remains undetermined, it is unclear 
whether there is an ideal method for measurement of glucose homeostasis and insulin sensitivity that 
can be applied across all breeds and types of horses.  Until the relative contributions of enteral 
absorption, pancreatic insulin secretion, and tissue insulin sensitivity to equine glucose homeostasis 
and insulin disposal can be established, no dynamic test of glucose tolerance or insulin sensitivity can 
be considered the gold standard.  Furthermore, results from dynamic tests should not be used 
interchangeably for diagnosis of equine insulin dysregulation. 
In conclusion, evidence presented here suggests that although EMS shares some phenotypic 
characteristics of human metabolic syndrome, the pathogenesis of the EMS may not be similar.  
Identification of the primary site of obesity-associated insulin dysregulation is critical to improve 
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